PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25338578-2 2014 The growth inhibitory rate, half inhibitory concentration (IC50), reversing multiples to adriamycin- resistance were detected by MTT, and the curve of growth inhibitory rate was drawn; the MDR-1 and MRP-1 gene transcription was determined by RT-PCR; the expressions of P-gp and MRP-1 proteins were assayed by Western blot and flow cytometry. Doxorubicin 89-99 ATP binding cassette subfamily C member 1 Homo sapiens 199-204 25603048-0 2015 ABCB1, ABCC1, and LRP gene expressions are altered by LDL, HDL, and serum deprivation in a human doxorubicin-resistant uterine sarcoma cell line. Doxorubicin 97-108 ATP binding cassette subfamily C member 1 Homo sapiens 7-12 25338578-4 2014 The reversing multiples to adriamycin-resistance were 255.7 multiples, the transcription of mdr-1 and mrp-1 genes and the expression of P-gp and MRP-1 proteins significantly decreased (P < 0.05) in Raji/ADR cells after the treatment with cinobufotalin. Doxorubicin 27-37 ATP binding cassette subfamily C member 1 Homo sapiens 102-107 25338578-4 2014 The reversing multiples to adriamycin-resistance were 255.7 multiples, the transcription of mdr-1 and mrp-1 genes and the expression of P-gp and MRP-1 proteins significantly decreased (P < 0.05) in Raji/ADR cells after the treatment with cinobufotalin. Doxorubicin 27-37 ATP binding cassette subfamily C member 1 Homo sapiens 145-150 25338578-5 2014 It is concluded that cinobufotalin can reverse the adriamycin-resistance in Raji/ADR cells and the expression of P-gp and MRP-1 proteins were down-regulated through the transcriptional pathway. Doxorubicin 51-61 ATP binding cassette subfamily C member 1 Homo sapiens 122-127 24161697-6 2014 Treatment with a combination of RSV and Dox significantly increased the cellular accumulation of Dox by down-regulating the expression levels of ATP-binding cassette (ABC) transporter genes, MDR1, and MRP1. Doxorubicin 40-43 ATP binding cassette subfamily C member 1 Homo sapiens 201-205 25105301-5 2014 Furthermore, lapatinib significantly increased the accumulation of rhodamine 123 (Rho123) and doxorubicin (DOX) in MRP1-overexpressing cells. Doxorubicin 94-105 ATP binding cassette subfamily C member 1 Homo sapiens 115-119 25105301-5 2014 Furthermore, lapatinib significantly increased the accumulation of rhodamine 123 (Rho123) and doxorubicin (DOX) in MRP1-overexpressing cells. Doxorubicin 107-110 ATP binding cassette subfamily C member 1 Homo sapiens 115-119 24491315-0 2014 Oleanolic and maslinic acid sensitize soft tissue sarcoma cells to doxorubicin by inhibiting the multidrug resistance protein MRP-1, but not P-glycoprotein. Doxorubicin 67-78 ATP binding cassette subfamily C member 1 Homo sapiens 126-131 25057799-5 2014 This event was accompanied in parallel by a higher release of NO, which caused nitration of P-glycoprotein (Pgp) and multidrug resistance related protein 1 (MRP1), two transporters involved in Dox efflux, and impaired their pump activity. Doxorubicin 193-196 ATP binding cassette subfamily C member 1 Homo sapiens 157-161 24161697-6 2014 Treatment with a combination of RSV and Dox significantly increased the cellular accumulation of Dox by down-regulating the expression levels of ATP-binding cassette (ABC) transporter genes, MDR1, and MRP1. Doxorubicin 97-100 ATP binding cassette subfamily C member 1 Homo sapiens 201-205 24956120-4 2014 All of them dramatically increased 6-carboxyfluorescein diacetate and doxorubicin accumulation in MRP1-transfected U-2 OS cells. Doxorubicin 70-81 ATP binding cassette subfamily C member 1 Homo sapiens 98-102 24040940-12 2013 In a subset of MPNSTs, high expression of ABCC1 is observed, serving as a predicted contra-indication for doxorubicin and related therapeutics in these patients. Doxorubicin 106-117 ATP binding cassette subfamily C member 1 Homo sapiens 42-47 23686318-8 2013 In addition, hsa-miR-1291-directed downregulation of ABCC1 led to a greater intracellular drug accumulation and sensitized the cells to doxorubicin. Doxorubicin 136-147 ATP binding cassette subfamily C member 1 Homo sapiens 53-58 22882382-4 2013 RESULTS: Our results showed that R-HepG2 cells, a doxorubicin-resistant sub-line of HepG2, exhibited decreased intracellular accumulation of doxorubicin and increased expression of P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 when compared with HepG2 cells. Doxorubicin 52-63 ATP binding cassette subfamily C member 1 Homo sapiens 199-250 32481901-11 2013 Reflux of the liberated free DOX in the cytosol, via an endosomal membrane transporter, is considered one of the reasons for the low efficiency of DOX@PNP chemotherapy against KB/MRP cells. Doxorubicin 29-32 ATP binding cassette subfamily C member 1 Homo sapiens 179-182 32481901-12 2013 However, compared to the free DOX dose, a high dose of the DOX@PNP was effectively delivered to the nuclei of the KB/MRP cells. Doxorubicin 30-33 ATP binding cassette subfamily C member 1 Homo sapiens 117-120 23320839-11 2013 Treatment of gemcitabine or doxorubicin activated phosphorylated ERK and induced the upregulation of MRP1 and MRP3. Doxorubicin 28-39 ATP binding cassette subfamily C member 1 Homo sapiens 101-105 22101388-3 2011 We observed that patients whose circulating tumor cells expressed MRP1 and MRP2, two drug-export pumps responsible for anthracyclines efflux, who received conventional anthracyclines had a significantly shorter time to progression compared with patients sharing same characteristics who received non pegylated liposomal doxorubicin (P < 0.005). Doxorubicin 320-331 ATP binding cassette subfamily C member 1 Homo sapiens 66-70 22787275-2 2012 In this study, we report that collagen/beta1 integrin signaling inhibits doxorubicin-induced apoptosis of Jurkat and HSB2 leukemic T-cells by up-regulating the expression and function of the ATP-binding cassette C 1 (ABCC1) transporter, also known as multidrug resistance-associated protein 1. Doxorubicin 73-84 ATP binding cassette subfamily C member 1 Homo sapiens 191-215 22787275-2 2012 In this study, we report that collagen/beta1 integrin signaling inhibits doxorubicin-induced apoptosis of Jurkat and HSB2 leukemic T-cells by up-regulating the expression and function of the ATP-binding cassette C 1 (ABCC1) transporter, also known as multidrug resistance-associated protein 1. Doxorubicin 73-84 ATP binding cassette subfamily C member 1 Homo sapiens 217-222 22787275-2 2012 In this study, we report that collagen/beta1 integrin signaling inhibits doxorubicin-induced apoptosis of Jurkat and HSB2 leukemic T-cells by up-regulating the expression and function of the ATP-binding cassette C 1 (ABCC1) transporter, also known as multidrug resistance-associated protein 1. Doxorubicin 73-84 ATP binding cassette subfamily C member 1 Homo sapiens 251-292 22787275-4 2012 Inhibition and knockdown studies show that up-regulation of ABCC1 is necessary for collagen-mediated reduction of intracellular doxorubicin content and collagen-mediated inhibition of doxorubicin-induced apoptosis. Doxorubicin 128-139 ATP binding cassette subfamily C member 1 Homo sapiens 60-65 22787275-4 2012 Inhibition and knockdown studies show that up-regulation of ABCC1 is necessary for collagen-mediated reduction of intracellular doxorubicin content and collagen-mediated inhibition of doxorubicin-induced apoptosis. Doxorubicin 184-195 ATP binding cassette subfamily C member 1 Homo sapiens 60-65 22510476-3 2012 After transfected A549 cells with miR-126 mimic or inhibitor, we found that an elevated level of miR-126 was significantly associated with a decreased half maximal inhibitory concentration of adriamycin (ADM) and vincristine, an increased accumulation of ADM, down-regulation of vascular endothelial growth factor A (VEGFA) and multidrug resistance-associated protein 1 (MRP1), and inactivation of the Akt signaling pathway. Doxorubicin 204-207 ATP binding cassette subfamily C member 1 Homo sapiens 328-369 22510476-3 2012 After transfected A549 cells with miR-126 mimic or inhibitor, we found that an elevated level of miR-126 was significantly associated with a decreased half maximal inhibitory concentration of adriamycin (ADM) and vincristine, an increased accumulation of ADM, down-regulation of vascular endothelial growth factor A (VEGFA) and multidrug resistance-associated protein 1 (MRP1), and inactivation of the Akt signaling pathway. Doxorubicin 204-207 ATP binding cassette subfamily C member 1 Homo sapiens 371-375 23320839-12 2013 MEK inhibitors U0126 and AZD6244 deactivated phosphorylated ERK, decreased endogenous MRP1 expression, reversed gemcitabine or doxorubicin induced MRP1 and MRP3 upregulation, and increased the intracellular doxorubicin accumulation. Doxorubicin 127-138 ATP binding cassette subfamily C member 1 Homo sapiens 147-151 22571463-3 2012 In consequence, the membrane transporter MRP1 was internalized from the cell surface into the cytoplasm, rendering cells sensitive to doxorubicin by more than 10-fold due to increased accumulation of doxorubicin in the cells. Doxorubicin 134-145 ATP binding cassette subfamily C member 1 Homo sapiens 41-45 22571463-3 2012 In consequence, the membrane transporter MRP1 was internalized from the cell surface into the cytoplasm, rendering cells sensitive to doxorubicin by more than 10-fold due to increased accumulation of doxorubicin in the cells. Doxorubicin 200-211 ATP binding cassette subfamily C member 1 Homo sapiens 41-45 22293538-0 2012 The G671V variant of MRP1/ABCC1 links doxorubicin-induced acute cardiac toxicity to disposition of the glutathione conjugate of 4-hydroxy-2-trans-nonenal. Doxorubicin 38-49 ATP binding cassette subfamily C member 1 Homo sapiens 21-25 22293538-0 2012 The G671V variant of MRP1/ABCC1 links doxorubicin-induced acute cardiac toxicity to disposition of the glutathione conjugate of 4-hydroxy-2-trans-nonenal. Doxorubicin 38-49 ATP binding cassette subfamily C member 1 Homo sapiens 26-31 22293538-1 2012 OBJECTIVE: Doxorubicin-induced acute cardiotoxicity is associated with the Gly671Val (G671V; rs45511401) variant of multidrug resistance-associated protein 1 (MRP1). Doxorubicin 11-22 ATP binding cassette subfamily C member 1 Homo sapiens 116-157 22293538-1 2012 OBJECTIVE: Doxorubicin-induced acute cardiotoxicity is associated with the Gly671Val (G671V; rs45511401) variant of multidrug resistance-associated protein 1 (MRP1). Doxorubicin 11-22 ATP binding cassette subfamily C member 1 Homo sapiens 159-163 22293538-10 2012 CONCLUSION: These data suggest that decreased MRP1-dependent GS-HNE efflux contributes to increased doxorubicin toxicity in HEKG671V and potentially in individuals carrying the G671V variant. Doxorubicin 100-111 ATP binding cassette subfamily C member 1 Homo sapiens 46-50 21566063-5 2011 In contrast, it had no effect on P-glycoprotein-mediated paclitaxel resistance in MDR1-transduced human leukemia K562 cells and multidrug resistance-related protein 1-mediated doxorubicin resistance in MRP1-transfected human epidermoid cancer KB-3-1 cells. Doxorubicin 176-187 ATP binding cassette subfamily C member 1 Homo sapiens 202-206 21679161-2 2011 In the present paper we illustrate that a doxorubicin-resistant human colon cancer cell line (HT29-DX), exhibiting decreased doxorubicin accumulation, increased intracellular GSH content, and increased MRP1 and MRP2 expression in comparison with doxorubicin-sensitive HT29 cells, shows increased activity of the PPP (pentose phosphate pathway) and of G6PD (glucose-6-phosphate dehydrogenase). Doxorubicin 42-53 ATP binding cassette subfamily C member 1 Homo sapiens 202-206 22094098-13 2011 But the sole treatment of RAD001 may inhibit proliferation, induce apoptosis and accumulate intercellular adriamycin through a down-regulated expression of MRP1 in HL60/ADM cells via an inhibition of PI3K/Akt/mTOR signaling pathway. Doxorubicin 106-116 ATP binding cassette subfamily C member 1 Homo sapiens 156-160 21903448-3 2011 We demonstrated that down-regulation of MRP1 in MC3/5FU, a drug-resistant MEC cell line, by RNA interference increased the drug sensitivity of the cells to 5-fluorouracil, doxorubicin, pharmorubicin, bleomycin-A5, cis-platinum and taxol. Doxorubicin 172-183 ATP binding cassette subfamily C member 1 Homo sapiens 40-44 21377266-0 2011 Indomethacin and SC236 enhance the cytotoxicity of doxorubicin in human hepatocellular carcinoma cells via inhibiting P-glycoprotein and MRP1 expression. Doxorubicin 51-62 ATP binding cassette subfamily C member 1 Homo sapiens 137-141 21571281-9 2011 Compared to DOX-free cancer cells, there was an acceleration of MRP1 expression during the 12h-exposure to DOX, after which the level of expression remained nearly constant as the intracellular accumulation of DOX decreased. Doxorubicin 12-15 ATP binding cassette subfamily C member 1 Homo sapiens 64-68 21571281-9 2011 Compared to DOX-free cancer cells, there was an acceleration of MRP1 expression during the 12h-exposure to DOX, after which the level of expression remained nearly constant as the intracellular accumulation of DOX decreased. Doxorubicin 107-110 ATP binding cassette subfamily C member 1 Homo sapiens 64-68 21571281-9 2011 Compared to DOX-free cancer cells, there was an acceleration of MRP1 expression during the 12h-exposure to DOX, after which the level of expression remained nearly constant as the intracellular accumulation of DOX decreased. Doxorubicin 107-110 ATP binding cassette subfamily C member 1 Homo sapiens 64-68 21377266-6 2011 Indomethacin and SC236 partially reversed the increase in expression of P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) induced by doxorubicin in R-HepG2 cells. Doxorubicin 158-169 ATP binding cassette subfamily C member 1 Homo sapiens 98-139 20350534-0 2010 Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of MRP1 expression. Doxorubicin 33-44 ATP binding cassette subfamily C member 1 Homo sapiens 110-114 21377266-6 2011 Indomethacin and SC236 partially reversed the increase in expression of P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) induced by doxorubicin in R-HepG2 cells. Doxorubicin 158-169 ATP binding cassette subfamily C member 1 Homo sapiens 141-145 20563580-0 2011 Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant MCF-7 cells. Doxorubicin 98-109 ATP binding cassette subfamily C member 1 Homo sapiens 90-94 21968975-1 2011 Incubation of the drug-sensitive H69, a small cell lung cancer cell line, with increased concentrations of adriamycin yielded multidrug resistant (MDR) H69AR cells that over-express multidrug resistance-associated protein (MRP1). Doxorubicin 107-117 ATP binding cassette subfamily C member 1 Homo sapiens 182-227 20532504-0 2010 Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Doxorubicin 214-225 ATP binding cassette subfamily C member 1 Homo sapiens 21-55 20339089-7 2010 We show that doxorubicin exposure to KMH2 induces ABCC1 expression and that siRNA silencing of ABCC1 sensitizes KMH2 cells to doxorubicin toxicity in vitro, suggesting that overexpression of ABCC1 contributes to the drug resistance phenotype found in KMH2. Doxorubicin 13-24 ATP binding cassette subfamily C member 1 Homo sapiens 50-55 20339089-7 2010 We show that doxorubicin exposure to KMH2 induces ABCC1 expression and that siRNA silencing of ABCC1 sensitizes KMH2 cells to doxorubicin toxicity in vitro, suggesting that overexpression of ABCC1 contributes to the drug resistance phenotype found in KMH2. Doxorubicin 126-137 ATP binding cassette subfamily C member 1 Homo sapiens 95-100 20339089-7 2010 We show that doxorubicin exposure to KMH2 induces ABCC1 expression and that siRNA silencing of ABCC1 sensitizes KMH2 cells to doxorubicin toxicity in vitro, suggesting that overexpression of ABCC1 contributes to the drug resistance phenotype found in KMH2. Doxorubicin 126-137 ATP binding cassette subfamily C member 1 Homo sapiens 95-100 21143116-7 2011 Cells that highly express MRP1/ABCC1 confer resistance to a variety of natural product anticancer drugs such as vinca alkaloids (e.g. vincristine), anthracyclines (e.g. etoposide) and epipodophyllotoxins (e.g. doxorubicin and mitoxantrone). Doxorubicin 210-221 ATP binding cassette subfamily C member 1 Homo sapiens 26-30 21143116-7 2011 Cells that highly express MRP1/ABCC1 confer resistance to a variety of natural product anticancer drugs such as vinca alkaloids (e.g. vincristine), anthracyclines (e.g. etoposide) and epipodophyllotoxins (e.g. doxorubicin and mitoxantrone). Doxorubicin 210-221 ATP binding cassette subfamily C member 1 Homo sapiens 31-36 20350534-6 2010 Importantly, the resveratrol was shown not only to induce cell growth arrest and apoptotic death in doxorubicin-resistant AML cells, but was also shown to downregulate the expression of an MRP1 gene. Doxorubicin 100-111 ATP binding cassette subfamily C member 1 Homo sapiens 189-193 20350534-7 2010 Furthermore, resveratrol treatment induced a significant increase in the uptake of 5(6)-carboxyfluorescein diacetate, a MRP1 substrate, into the doxorubicin-resistant AML-2/DX300 cells. Doxorubicin 145-156 ATP binding cassette subfamily C member 1 Homo sapiens 120-124 20350534-8 2010 The results of this study show that resveratrol may facilitate the cellular uptake of doxorubicin via an induced downregulation of MRP1 expression, and also suggest that it may prove useful in overcoming doxorubicin resistance, or in sensitizing doxorubicin-resistant AML cells to anti-leukemic agents. Doxorubicin 86-97 ATP binding cassette subfamily C member 1 Homo sapiens 131-135 19120455-11 2009 The innate resistance provided by MRP1 to cells prevents rhodamine dyes, and possibly drugs such as doxorubicin, from achieving equilibration of their concentration in the cytoplasm with their concentration in the external medium. Doxorubicin 100-111 ATP binding cassette subfamily C member 1 Homo sapiens 34-38 20037485-7 2010 The QRT - PCR analysis has shown that, when used simultaneously, DOX 1 microM and SUL 50 microM results in decreased mRNA level for MDR-1 and MRP-1. Doxorubicin 65-68 ATP binding cassette subfamily C member 1 Homo sapiens 142-147 20037485-9 2010 The observed effect is due to quenching of MDR-1 and MRP-1 genes expression, which results in blocking of efflux of DOX outside the cells, which in turn correlates with enhanced apoptotic effects. Doxorubicin 116-119 ATP binding cassette subfamily C member 1 Homo sapiens 53-58 18828019-5 2009 In contrast, the doxorubicin selected resistant cell lines also expressed high level of ABCB1 (but not ABCC1 or ABCG2) but did demonstrate significant cross-resistance to both ET-743 and PM00104. Doxorubicin 17-28 ATP binding cassette subfamily C member 1 Homo sapiens 103-108 19214144-7 2009 None of these mutations had any effect on MRP1/ABCC1 expression and trafficking, but that Arg723Gln mutation significantly reduced MRP1/ABCC1-mediated resistance to daunorubicin, doxorubicin, etoposide, vinblastine, and vincristine. Doxorubicin 179-190 ATP binding cassette subfamily C member 1 Homo sapiens 131-135 20137116-1 2010 This study was purposed to investigate the effects of compound Zhe-Bei granule (CZBG) combined with doxorubicin on expressions of P-gp, MRP, LRP in K562/A02 cell xenografts. Doxorubicin 100-111 ATP binding cassette subfamily C member 1 Homo sapiens 136-139 19725578-1 2009 Here we showed that bivalency approach is effective in modulating multidrug resistance protein 1 (MRP1/ABCC1)-mediated doxorubicin (DOX) and etoposide (VP16) resistance in human 2008/MRP1 ovarian carcinoma cells. Doxorubicin 119-130 ATP binding cassette subfamily C member 1 Homo sapiens 98-102 19725578-1 2009 Here we showed that bivalency approach is effective in modulating multidrug resistance protein 1 (MRP1/ABCC1)-mediated doxorubicin (DOX) and etoposide (VP16) resistance in human 2008/MRP1 ovarian carcinoma cells. Doxorubicin 119-130 ATP binding cassette subfamily C member 1 Homo sapiens 103-108 19725578-1 2009 Here we showed that bivalency approach is effective in modulating multidrug resistance protein 1 (MRP1/ABCC1)-mediated doxorubicin (DOX) and etoposide (VP16) resistance in human 2008/MRP1 ovarian carcinoma cells. Doxorubicin 132-135 ATP binding cassette subfamily C member 1 Homo sapiens 98-102 19725578-1 2009 Here we showed that bivalency approach is effective in modulating multidrug resistance protein 1 (MRP1/ABCC1)-mediated doxorubicin (DOX) and etoposide (VP16) resistance in human 2008/MRP1 ovarian carcinoma cells. Doxorubicin 132-135 ATP binding cassette subfamily C member 1 Homo sapiens 103-108 19725578-3 2009 At 0.5 microM, the flavonoid dimer 4e was sufficient to restore DOX accumulation in 2008/MRP1 to parental 2008/P level. Doxorubicin 64-67 ATP binding cassette subfamily C member 1 Homo sapiens 89-93 19725578-5 2009 Our data suggest that flavonoid dimers have a high affinity toward binding to DOX recognition site of MRP1. Doxorubicin 78-81 ATP binding cassette subfamily C member 1 Homo sapiens 102-106 19725578-6 2009 This results in inhibiting DOX transport, increasing intracellular DOX retention, and finally resensitizing 2008/MRP1 to DOX. Doxorubicin 27-30 ATP binding cassette subfamily C member 1 Homo sapiens 113-117 19725578-6 2009 This results in inhibiting DOX transport, increasing intracellular DOX retention, and finally resensitizing 2008/MRP1 to DOX. Doxorubicin 67-70 ATP binding cassette subfamily C member 1 Homo sapiens 113-117 19725578-6 2009 This results in inhibiting DOX transport, increasing intracellular DOX retention, and finally resensitizing 2008/MRP1 to DOX. Doxorubicin 67-70 ATP binding cassette subfamily C member 1 Homo sapiens 113-117 19390592-7 2009 Flow cytometric analysis showed that vandetanib treatment significantly increase the intracellular accumulation of doxorubicin and rhodamine 123, substrates of ABCC1 and ABCG2 respectively, in a dose-dependent manner (P<0.05). Doxorubicin 115-126 ATP binding cassette subfamily C member 1 Homo sapiens 160-165 18924151-4 2009 Two new drug-resistant cell lines were generated following exposure to doxorubicin or daunorubicin and these upregulated MRP1 or P-glycoprotein expression, respectively. Doxorubicin 71-82 ATP binding cassette subfamily C member 1 Homo sapiens 121-125 19175986-7 2008 PH II -7 and doxorubicin act synergistically in inhibiting the proliferation of HL-60 and HL-60/ADR cells and down-regulating the expression of MRP gene in a dose and time dependent manner. Doxorubicin 13-24 ATP binding cassette subfamily C member 1 Homo sapiens 144-147 19175986-9 2008 CONCLUSION: PH II -7 can significantly hasten the cytotoxicity of doxorubicin to HL-60 and HL-60/ADR cells through down-regulating the expression of MRP. Doxorubicin 66-77 ATP binding cassette subfamily C member 1 Homo sapiens 149-152 16410038-8 2006 CuNG, a known depleting agent for glutathione (GSH) and inhibitor of glutathione S-transferase (GST) and multidrug resistance-related protein 1 (MRP1), also inhibited P-gp-mediated doxorubicin accumulation and retention. Doxorubicin 181-192 ATP binding cassette subfamily C member 1 Homo sapiens 145-149 17072745-1 2007 BACKGROUND: The synthetic 4"-O-benzylated doxorubicin analog WP744 was designed to abrogate transport by the multidrug resistance (MDR)-associated ATP-binding cassette (ABC) proteins P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1). Doxorubicin 42-53 ATP binding cassette subfamily C member 1 Homo sapiens 238-243 17129588-3 2007 The activities of 5 dibenzocyclooctadiene lignans (schisandrin A, schisandrin B, schisantherin A, schisandrol A, and schisandrol B) to reverse MRP1-mediated drug resistance were tested using HL60/Adriamycin (ADR) and HL60/Multidrug resistance-associated protein (MRP), two human promyelocytic leukemia cell lines with overexpression of MRP1 but not P-gp. Doxorubicin 196-206 ATP binding cassette subfamily C member 1 Homo sapiens 143-147 17129588-3 2007 The activities of 5 dibenzocyclooctadiene lignans (schisandrin A, schisandrin B, schisantherin A, schisandrol A, and schisandrol B) to reverse MRP1-mediated drug resistance were tested using HL60/Adriamycin (ADR) and HL60/Multidrug resistance-associated protein (MRP), two human promyelocytic leukemia cell lines with overexpression of MRP1 but not P-gp. Doxorubicin 196-206 ATP binding cassette subfamily C member 1 Homo sapiens 143-146 18560228-2 2008 METHODS: Doxorubicin-resistant MCF-7/R was developed from sensitive MCF-7 breast carcinoma cell line and acquired resistance was demonstrated by XTT and mRNA analysis of MDR1 and MRP1 genes. Doxorubicin 9-20 ATP binding cassette subfamily C member 1 Homo sapiens 179-183 18560228-5 2008 RESULTS: Doxorubicin-selected MCF-7 cells were 107-fold resistant to the drug and overexpress MDR1 and MRP1 genes. Doxorubicin 9-20 ATP binding cassette subfamily C member 1 Homo sapiens 103-107 20020937-5 2008 Finally, a polarized transport of doxorubicin from basal to apical side was evident, although only during the first 60 min of incubation, and was reduced by P-glycoprotein, MRP, and BCRP inhibitors. Doxorubicin 34-45 ATP binding cassette subfamily C member 1 Homo sapiens 173-176 17520676-5 2007 Here, we demonstrated that flavopiridol induced the cleavage of poly-ADP-ribose polymerase (PARP) in a time and dose dependent manner in adriamycin-resistant OS and EFTs cells expressing P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP(1)) as effectively as in their parental cells. Doxorubicin 137-147 ATP binding cassette subfamily C member 1 Homo sapiens 213-254 17520676-5 2007 Here, we demonstrated that flavopiridol induced the cleavage of poly-ADP-ribose polymerase (PARP) in a time and dose dependent manner in adriamycin-resistant OS and EFTs cells expressing P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP(1)) as effectively as in their parental cells. Doxorubicin 137-147 ATP binding cassette subfamily C member 1 Homo sapiens 256-262 17352253-0 2007 Modulatory effects of heparin on cellular accumulation and cytotoxicity of doxorubicin in MRP1-overexpressing HL60/doxo cells. Doxorubicin 75-86 ATP binding cassette subfamily C member 1 Homo sapiens 90-94 17352253-5 2007 MATERIALS AND METHODS: The human leukemic doxorubicin-resistant cell line (HL60/doxo), which overexpresses the MRP1 protein was treated with UFH alone or in combination with three different concentrations of doxo. Doxorubicin 42-53 ATP binding cassette subfamily C member 1 Homo sapiens 111-115 16202586-2 2005 These studies ultimately identified compound 21b, which reverses drug resistance to MRP1 substrates, such as doxorubicin, in HeLa-T5 cells (EC(50)=0.093microM), while showing no inherent cytotoxicity. Doxorubicin 109-120 ATP binding cassette subfamily C member 1 Homo sapiens 84-88 16263302-5 2006 These derivatives each used at 4muM (a non-cytotoxic concentration) enhance significantly the sensitivity of hMRP1-mediated MDR cell line toward doxorubicin toxicity. Doxorubicin 145-156 ATP binding cassette subfamily C member 1 Homo sapiens 109-114 16049968-5 2006 Here, we demonstrated that FK228 and apicidin exhibited strong resistance in doxorubicin-resistant clones of OS and EFTs expressing P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) and that P-gp and MRP1 might play a crucial role in the resistance mechanism to FK228 and apicidin. Doxorubicin 77-88 ATP binding cassette subfamily C member 1 Homo sapiens 158-199 16049968-5 2006 Here, we demonstrated that FK228 and apicidin exhibited strong resistance in doxorubicin-resistant clones of OS and EFTs expressing P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) and that P-gp and MRP1 might play a crucial role in the resistance mechanism to FK228 and apicidin. Doxorubicin 77-88 ATP binding cassette subfamily C member 1 Homo sapiens 201-205 16049968-5 2006 Here, we demonstrated that FK228 and apicidin exhibited strong resistance in doxorubicin-resistant clones of OS and EFTs expressing P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) and that P-gp and MRP1 might play a crucial role in the resistance mechanism to FK228 and apicidin. Doxorubicin 77-88 ATP binding cassette subfamily C member 1 Homo sapiens 225-229 15152944-0 2004 Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer. Doxorubicin 34-45 ATP binding cassette subfamily C member 1 Homo sapiens 101-106 15880572-0 2005 Doxorubicin induces expression of multidrug resistance-associated protein 1 in human small cell lung cancer cell lines by the c-jun N-terminal kinase pathway. Doxorubicin 0-11 ATP binding cassette subfamily C member 1 Homo sapiens 34-75 15880572-3 2005 A number of chemotherapeutic agents including doxorubicin (DOX) were reported to induce MRP1 expression in human lung cancer cells. Doxorubicin 46-57 ATP binding cassette subfamily C member 1 Homo sapiens 88-92 15880572-3 2005 A number of chemotherapeutic agents including doxorubicin (DOX) were reported to induce MRP1 expression in human lung cancer cells. Doxorubicin 59-62 ATP binding cassette subfamily C member 1 Homo sapiens 88-92 15880572-4 2005 In our study, we investigated the mechanism by which DOX induces MRP1 expression in human small cell lung cancer (SCLC) cell lines, GLC4 and NCI-H82. Doxorubicin 53-56 ATP binding cassette subfamily C member 1 Homo sapiens 65-69 15880572-6 2005 Doxorubicin at 50 nM induced a marked increase in MRP1 expression in 24 hr, and stimulated c-jun N-terminal kinase (JNK) activity. Doxorubicin 0-11 ATP binding cassette subfamily C member 1 Homo sapiens 50-54 15880572-8 2005 Furthermore, transfection with JNK1 and JNK2 antisense oligonucleotides markedly inhibited DOX-induced MRP1 expression. Doxorubicin 91-94 ATP binding cassette subfamily C member 1 Homo sapiens 103-107 15880572-9 2005 Chromatin immunoprecipitation assays revealed an enhanced recruitment of phosphorylated c-jun to the MRP1 promoter containing the AP-1 site upon DOX stimulation, which was inhibited by pretreatment with SP600125. Doxorubicin 145-148 ATP binding cassette subfamily C member 1 Homo sapiens 101-105 15880572-10 2005 Surprisingly, GLC4 cells exposed to DOX for 24 hr maintained increased MRP1 expression and resistance to DOX for at least 3 weeks. Doxorubicin 36-39 ATP binding cassette subfamily C member 1 Homo sapiens 71-75 16170027-4 2005 The COX-2 inhibitor celecoxib down-regulated the expression of MRP1 protein in A549 cells, which was accompanied by increased accumulation and enhanced cytotoxicity of doxorubicin, an MRP1 substrate. Doxorubicin 168-179 ATP binding cassette subfamily C member 1 Homo sapiens 63-67 16170027-4 2005 The COX-2 inhibitor celecoxib down-regulated the expression of MRP1 protein in A549 cells, which was accompanied by increased accumulation and enhanced cytotoxicity of doxorubicin, an MRP1 substrate. Doxorubicin 168-179 ATP binding cassette subfamily C member 1 Homo sapiens 184-188 15942634-1 2005 Clinical usefulness of doxorubicin (DOX) is limited by the occurrence of multidrug resistance (MDR) associated with the presence of membrane transporters (e.g. P-glycoprotein, MRP1) responsible for the active efflux of drugs out of resistant cells. Doxorubicin 23-34 ATP binding cassette subfamily C member 1 Homo sapiens 176-180 15942634-1 2005 Clinical usefulness of doxorubicin (DOX) is limited by the occurrence of multidrug resistance (MDR) associated with the presence of membrane transporters (e.g. P-glycoprotein, MRP1) responsible for the active efflux of drugs out of resistant cells. Doxorubicin 36-39 ATP binding cassette subfamily C member 1 Homo sapiens 176-180 15942634-8 2005 In the second part of this work, the ability of DOX to inhibit the growth of human promyelocytic-sensitive leukaemia HL60 cell line as well as its MDR sublines exhibiting two different phenotypes of MDR related to the overexpression of P-glycoprotein (HL60/VINC) or MRP1 (HL60/DOX) was studied in the presence of exogenously added CPR. Doxorubicin 48-51 ATP binding cassette subfamily C member 1 Homo sapiens 266-270 15006547-6 2004 The labeling of the 190kDa MRP1 protein in membranes of HeLa-T5 cells was inhibited by substrates of MRP1 such as leukotriene C(4), vincrisine, and doxorubicin and by the inhibitor, MK571. Doxorubicin 148-159 ATP binding cassette subfamily C member 1 Homo sapiens 27-31 15946544-3 2005 mRNA expressions of P-glycoprotein (MDR1), glutathione S-transferase Pi (GSTpi) and MDR-associated protein (MRP) of K562/Dox treated with Hal were assayed by RT-PCR. Doxorubicin 121-124 ATP binding cassette subfamily C member 1 Homo sapiens 108-111 15473893-0 2004 N-acetylcysteine enhances multidrug resistance-associated protein 1 mediated doxorubicin resistance. Doxorubicin 77-88 ATP binding cassette subfamily C member 1 Homo sapiens 26-67 15473893-5 2004 The aim of our study was to investigate the effect of NAC and BSO on MRP1-mediated doxorubicin resistance in human embryonic kidney (HEK293) and its MRP1-transfected 293MRP cells. Doxorubicin 83-94 ATP binding cassette subfamily C member 1 Homo sapiens 69-73 15473893-11 2004 DL-buthionine (S,R)-sulfoximine decreased NAC-enhanced MRP1-mediated doxorubicin resistance, indicating that induction of MRP1-mediated doxorubicin resistance depends on GSH synthesis. Doxorubicin 69-80 ATP binding cassette subfamily C member 1 Homo sapiens 55-59 15473893-11 2004 DL-buthionine (S,R)-sulfoximine decreased NAC-enhanced MRP1-mediated doxorubicin resistance, indicating that induction of MRP1-mediated doxorubicin resistance depends on GSH synthesis. Doxorubicin 136-147 ATP binding cassette subfamily C member 1 Homo sapiens 122-126 15473893-14 2004 CONCLUSION: Our results demonstrate that NAC enhances MRP1-mediated doxorubicin resistance and this effect depends on GSH synthesis. Doxorubicin 68-79 ATP binding cassette subfamily C member 1 Homo sapiens 54-58 15233869-7 2004 Finally, the expression of MDR genes (MDR1 and MRP1) in MCF-7/dox cells following the exposure to doxorubicin alone and in combination with monensin liposomes was evaluated by semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). Doxorubicin 62-65 ATP binding cassette subfamily C member 1 Homo sapiens 47-51 15233869-7 2004 Finally, the expression of MDR genes (MDR1 and MRP1) in MCF-7/dox cells following the exposure to doxorubicin alone and in combination with monensin liposomes was evaluated by semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). Doxorubicin 98-109 ATP binding cassette subfamily C member 1 Homo sapiens 47-51 15233869-11 2004 RT-PCR studies demonstrated that the expression of MDR1 and MRP1 was increased by 33 and 57%, respectively, in MCF-7/dox cells following treatment with doxorubicin (2.5 microg mL(-1)) for 72 h as compared with control MCF-7/dox cells. Doxorubicin 117-120 ATP binding cassette subfamily C member 1 Homo sapiens 60-64 15233869-11 2004 RT-PCR studies demonstrated that the expression of MDR1 and MRP1 was increased by 33 and 57%, respectively, in MCF-7/dox cells following treatment with doxorubicin (2.5 microg mL(-1)) for 72 h as compared with control MCF-7/dox cells. Doxorubicin 152-163 ATP binding cassette subfamily C member 1 Homo sapiens 60-64 15233869-11 2004 RT-PCR studies demonstrated that the expression of MDR1 and MRP1 was increased by 33 and 57%, respectively, in MCF-7/dox cells following treatment with doxorubicin (2.5 microg mL(-1)) for 72 h as compared with control MCF-7/dox cells. Doxorubicin 152-155 ATP binding cassette subfamily C member 1 Homo sapiens 60-64 15233869-12 2004 Furthermore, the levels of MDR1 and MRP1 in MCF-7/dox cells exposed to both doxorubicin and monensin liposomes showed a modest decrease as compared with MCF-7/dox cells treated with doxorubicin alone. Doxorubicin 50-53 ATP binding cassette subfamily C member 1 Homo sapiens 36-40 15233869-12 2004 Furthermore, the levels of MDR1 and MRP1 in MCF-7/dox cells exposed to both doxorubicin and monensin liposomes showed a modest decrease as compared with MCF-7/dox cells treated with doxorubicin alone. Doxorubicin 76-87 ATP binding cassette subfamily C member 1 Homo sapiens 36-40 15233869-12 2004 Furthermore, the levels of MDR1 and MRP1 in MCF-7/dox cells exposed to both doxorubicin and monensin liposomes showed a modest decrease as compared with MCF-7/dox cells treated with doxorubicin alone. Doxorubicin 76-79 ATP binding cassette subfamily C member 1 Homo sapiens 36-40 15233869-12 2004 Furthermore, the levels of MDR1 and MRP1 in MCF-7/dox cells exposed to both doxorubicin and monensin liposomes showed a modest decrease as compared with MCF-7/dox cells treated with doxorubicin alone. Doxorubicin 182-193 ATP binding cassette subfamily C member 1 Homo sapiens 36-40 15198509-7 2004 The rMRP1 transfected cells, like their human ortholog, can confer drug resistance to vinca alkaloid (vinblastine and vincristine) and anthracycline drugs (daunorubcin and doxorubicin), and the resistance conferred by the MRP1 can be partially abolished by the MRP-specific inhibitors. Doxorubicin 172-183 ATP binding cassette subfamily C member 1 Homo sapiens 5-9 15198509-7 2004 The rMRP1 transfected cells, like their human ortholog, can confer drug resistance to vinca alkaloid (vinblastine and vincristine) and anthracycline drugs (daunorubcin and doxorubicin), and the resistance conferred by the MRP1 can be partially abolished by the MRP-specific inhibitors. Doxorubicin 172-183 ATP binding cassette subfamily C member 1 Homo sapiens 5-8 15152944-4 2004 NCI H460 cells expressed MRP-1 protein (by Western blot) and also the toxicity of doxorubicin (a substrate of MRP-1) could be potentiated in this line using non-toxic concentrations of the MRP-1 substrate/inhibitor sulindac. Doxorubicin 82-93 ATP binding cassette subfamily C member 1 Homo sapiens 110-115 15152944-4 2004 NCI H460 cells expressed MRP-1 protein (by Western blot) and also the toxicity of doxorubicin (a substrate of MRP-1) could be potentiated in this line using non-toxic concentrations of the MRP-1 substrate/inhibitor sulindac. Doxorubicin 82-93 ATP binding cassette subfamily C member 1 Homo sapiens 110-115 15152944-6 2004 RESULTS: Sulindac was shown to significantly potentiate the tumour growth inhibitor activity of doxorubicin in this MRP-1-overexpressing human tumour xenograft model. Doxorubicin 96-107 ATP binding cassette subfamily C member 1 Homo sapiens 116-121 12088114-10 2002 In agreement, hCPT increased also the DNR nuclear accumulation in low MRP1-expressing MCF7/DOX cells. Doxorubicin 91-94 ATP binding cassette subfamily C member 1 Homo sapiens 70-74 14655754-5 2003 Inhibition of MRP activity by indomethacin or probenecid enhanced the cytotoxic effects of vincristine, doxorubicin and teniposide. Doxorubicin 104-115 ATP binding cassette subfamily C member 1 Homo sapiens 14-17 12964004-0 2003 Enhanced cytotoxicity and nuclear accumulation of doxorubicin-loaded nanospheres in human breast cancer MCF7 cells expressing MRP1. Doxorubicin 50-61 ATP binding cassette subfamily C member 1 Homo sapiens 126-130 14620511-5 2003 RESULTS: Considerable increases of vinblastine and doxorubicin accumulation in the cells overexpressing MRP1 and MRP2 in the presence of P85 were observed, although no statistically significant changes in drug accumulation in the parental cells were found. Doxorubicin 51-62 ATP binding cassette subfamily C member 1 Homo sapiens 104-108 12799644-5 2003 The doxorubicin-resistant cells 2R120 (MRP1) and 2R160 (P-gP) were nine- and 28-fold more sensitive to gemcitabine than their parental SW1573 cells, respectively (P<0.01), which was completely reverted by 25 micro M verapamil. Doxorubicin 4-15 ATP binding cassette subfamily C member 1 Homo sapiens 39-43 12632060-9 2003 Inhibition of DOX transport by anti-MRP and anti-Pgp antibody was 35+/-7% (n=12) and 2+/-0.3% (n=12), respectively. Doxorubicin 14-17 ATP binding cassette subfamily C member 1 Homo sapiens 36-39 12632074-5 2003 The hammerhead ribozyme-mediated specific suppression of MRP1 was sufficient to reverse the resistance of ACNU and DOX in the human glioma cell line. Doxorubicin 115-118 ATP binding cassette subfamily C member 1 Homo sapiens 57-61 12576456-8 2003 However, in the subgroup of patients treated with anthracycline-based chemotherapy (5-fluorouracil, Adriamycin/epirubicin, and cyclophosphamide), a correlation between response and the expression of BCRP and MRP1 (only PFS) was found, whereas such an association was not present in the cyclophosphamide, methotrexate, and 5-fluorouracil-treated group of patients. Doxorubicin 100-110 ATP binding cassette subfamily C member 1 Homo sapiens 208-212 12042670-0 2002 A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Doxorubicin 115-126 ATP binding cassette subfamily C member 1 Homo sapiens 34-38 12042670-8 2002 In contrast to the reduced LTC4 and oestrone sulphate transport, stably transfected HeLa cells expressing Arg433Ser mutant MRP1 were 2.1-fold more resistant to doxorubicin than cells expressing wild-type MRP1, while resistance to VP-16 and vincristine was unchanged. Doxorubicin 160-171 ATP binding cassette subfamily C member 1 Homo sapiens 123-127 12085207-0 2002 Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Doxorubicin 155-166 ATP binding cassette subfamily C member 1 Homo sapiens 14-54 12085207-2 2002 In a variety of malignancies, high expression of multidrug resistance-associated protein1 and P-glycoprotein has been associated with resistance to doxorubicin, whereas 5-fluorouracil resistance has correlated with the level of thymidylate synthase expression. Doxorubicin 148-159 ATP binding cassette subfamily C member 1 Homo sapiens 49-89 12647018-6 2003 Transfection with antisense MRP1 oligonucleotides demonstrated a DOX sensitization effect (about 2-fold) in p53-R175H transfectants but not in control cells. Doxorubicin 65-68 ATP binding cassette subfamily C member 1 Homo sapiens 28-32 11410522-2 2001 Cancer Res., 5: 673-680, 1999), we found, in a panel of 23 lung cancer cell lines that had not been selected for in vitro drug resistance, that the mRNA levels of MRP3 and MRP1, two members of the ATP-binding cassette superfamily of transport proteins, correlated with resistance to doxorubicin, vincristine, VP-16, and cis-diamminedicholoroplatinum(II). Doxorubicin 283-294 ATP binding cassette subfamily C member 1 Homo sapiens 172-176 11351295-0 2001 Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance. Doxorubicin 111-122 ATP binding cassette subfamily C member 1 Homo sapiens 57-98 11351295-1 2001 While P-glycoprotein (Pgp) and multidrug resistance-associated protein 1 (MRP1) are known to be important in acquired doxorubicin resistance, the role of glutathione S-transferases (GST) remains unclear. Doxorubicin 118-129 ATP binding cassette subfamily C member 1 Homo sapiens 31-72 11351295-1 2001 While P-glycoprotein (Pgp) and multidrug resistance-associated protein 1 (MRP1) are known to be important in acquired doxorubicin resistance, the role of glutathione S-transferases (GST) remains unclear. Doxorubicin 118-129 ATP binding cassette subfamily C member 1 Homo sapiens 74-78 11351295-5 2001 In the resistant HEp2A cells, cytotoxicity was markedly enhanced by the Pgp/MRP inhibitor verapamil at low doxorubicin concentrations. Doxorubicin 107-118 ATP binding cassette subfamily C member 1 Homo sapiens 76-79 11920626-1 2002 Overexpression of the P-glycoprotein/multidrug resistance 1 (MDR1) and multidrug resistance protein 1 (MRP1) gene is closely associated with the clinical outcome of various malignancies, and it is involved in responses to some anticancer chemotherapeutic agents including doxorubicin. Doxorubicin 272-283 ATP binding cassette subfamily C member 1 Homo sapiens 103-107 11920626-7 2002 Using 47 clinical samples of bladder cancer, we confirmed the significant correlation of MDR1, MRP1 and MRP3 mRNA levels with resistance to doxorubicin. Doxorubicin 140-151 ATP binding cassette subfamily C member 1 Homo sapiens 95-99 11958985-2 2002 From a screen lead, SAR efforts resulted in the preparation of LY 402913 (9h), which inhibits MRP1 and reverses drug resistance to MRP1 substrates, such as doxorubicin, in HeLa-T5 cells (EC(50)=0.90 microM), while showing no inherent cytotoxicity. Doxorubicin 156-167 ATP binding cassette subfamily C member 1 Homo sapiens 131-135 11408511-15 2001 The safety and pharmacokinetics of VX-710 plus doxorubicin warrant efficacy trials in malignancies expressing P-gp and/or MRP1. Doxorubicin 47-58 ATP binding cassette subfamily C member 1 Homo sapiens 122-126 11410522-8 2001 Finally, we found that both MRP3 and MRP1, but not MRP2, protein levels correlated with decreased sensitivity of these lung cancer cell lines to doxorubicin, VCR, VP-16, and cis-diamminedicholoroplatinum(II). Doxorubicin 145-156 ATP binding cassette subfamily C member 1 Homo sapiens 37-41 11112520-6 2000 Furthermore, the photoaffinity labeling of MRP1 with IAARh123 was greatly reduced in the presence of excess Leukotreine C(4) or MK571, but to a lesser extent with excess doxorubicin, colchicine or chloroquine. Doxorubicin 170-181 ATP binding cassette subfamily C member 1 Homo sapiens 43-47 11322768-3 2001 This study attempted not only to determine novel resistance mechanisms in MRP-overexpressing AML cells (AML-2/DX100) by chronic exposure to doxorubicin in the presence of an MRP inhibitor probenecid but also to find out whether probenecid could increase MRP levels. Doxorubicin 140-151 ATP binding cassette subfamily C member 1 Homo sapiens 74-77 11278000-8 2001 Binding of drugs (4-demethoxy-daunorubicin and 3"-(3-methoxymorpholino)doxorubicin) which accumulate in resistant cells immobilizes MRP1 in a conformational state that is insensitive to ATP binding whereas drugs rejected outside the resistant cells (daunorubicin, doxorubicin) favor a conformational change which may be a required step in the transport process. Doxorubicin 71-82 ATP binding cassette subfamily C member 1 Homo sapiens 132-136 11178967-2 2001 The previous study revealed that a doxorubicin-resistant AML subline (AML-2/DX100) overexpressed an MDR-associated protein (MRP) but not P-glycoprotein. Doxorubicin 35-46 ATP binding cassette subfamily C member 1 Homo sapiens 100-122 11178967-2 2001 The previous study revealed that a doxorubicin-resistant AML subline (AML-2/DX100) overexpressed an MDR-associated protein (MRP) but not P-glycoprotein. Doxorubicin 35-46 ATP binding cassette subfamily C member 1 Homo sapiens 124-127 10556489-1 1999 The ATP-binding cassette transporter protein, multidrug resistance protein MRP1, was purified from doxorubicin-selected H69AR lung tumor cells which express high levels of this protein. Doxorubicin 99-110 ATP binding cassette subfamily C member 1 Homo sapiens 75-79 10821682-7 2000 Furthermore, a molar excess of leukotriene C(4), doxorubicin, colchicine, and other quinoline-based drugs, including MK571, inhibited the photoaffinity labeling of the MRP. Doxorubicin 49-60 ATP binding cassette subfamily C member 1 Homo sapiens 168-171 10612603-1 1999 The benzothiophene LY329146 reverses the drug resistance phenotype in multidrug resistance protein (MRP1)-overexpressing cells when dosed in combination with MRP1-associated oncolytics doxorubicin and vincristine. Doxorubicin 185-196 ATP binding cassette subfamily C member 1 Homo sapiens 158-162 10200335-5 1999 Chang liver cells with highest GSH content and highest activities of GST, GSH-RD, GSHpx and GS-X pump were most resistant to both adriamycin and chlorambucil. Doxorubicin 130-140 ATP binding cassette subfamily C member 1 Homo sapiens 92-96 10200335-0 1999 GSH, GSH-related enzymes and GS-X pump in relation to sensitivity of human tumor cell lines to chlorambucil and adriamycin. Doxorubicin 112-122 ATP binding cassette subfamily C member 1 Homo sapiens 29-33 10428874-6 1999 However, only those in which the COOH-terminal third of mrp had been replaced with the corresponding region of MRP-conferred resistance to the anthracyclines, doxorubicin, and epirubicin. Doxorubicin 159-170 ATP binding cassette subfamily C member 1 Homo sapiens 56-59 10428874-6 1999 However, only those in which the COOH-terminal third of mrp had been replaced with the corresponding region of MRP-conferred resistance to the anthracyclines, doxorubicin, and epirubicin. Doxorubicin 159-170 ATP binding cassette subfamily C member 1 Homo sapiens 111-114 10100721-5 1999 Using both SCLC and non-SCLC cell lines, we confirmed the previously observed correlation of MRP mRNA levels with resistance to DOX (B. G. Campling et al., Clin. Doxorubicin 128-131 ATP binding cassette subfamily C member 1 Homo sapiens 93-96 10200335-4 1999 IC50 values of adriamycin were also positively correlated to GSH contents and activities of GSH-RD, GSHpx and GS-X pump with r values ranging from 0.66 to 0.77 but not to GST activity (r=0.25). Doxorubicin 15-25 ATP binding cassette subfamily C member 1 Homo sapiens 110-114 9113101-3 1997 The present study examined the effect of BCNU on the MRP-mediated efflux of doxorubicin in the multidrug-resistant human fibrosarcoma cell line HT1080/DR4 overexpressing MRP. Doxorubicin 76-87 ATP binding cassette subfamily C member 1 Homo sapiens 53-56 10049760-5 1999 In both resistant and unselected cell lines expressing the MRP gene, MS-209 increased [3H]vincristine accumulation in proportion with the level of MRP mRNA expression and enhanced the cytotoxicity of etoposide, doxorubicin, and vincristine. Doxorubicin 211-222 ATP binding cassette subfamily C member 1 Homo sapiens 59-62 9923448-9 1999 Southern blot analysis of the gene organization in the HL60/DOX cells revealed the amplification of MRP gene. Doxorubicin 60-63 ATP binding cassette subfamily C member 1 Homo sapiens 100-103 9923448-10 1999 These results indicate that alteration of the drug accumulation from enhanced efflux appears to be a major mechanism(s) of MDR phenotype and attributable to high levels of MRP expression in the HL60/DOX cells. Doxorubicin 199-202 ATP binding cassette subfamily C member 1 Homo sapiens 172-175 9835508-3 1998 HIV PIs also enhanced the cytotoxic activity of doxorubicin, a known substrate for MDR1 and MRP1, in both VBL100 and VM-1-5 CEM lines. Doxorubicin 48-59 ATP binding cassette subfamily C member 1 Homo sapiens 92-96 9763226-0 1998 S9788 modulation of P-glycoprotein- and Multidrug-related protein-mediated multidrug resistance by Servier 9788 in doxorubicin-resistant MCF7 cells. Doxorubicin 115-126 ATP binding cassette subfamily C member 1 Homo sapiens 40-65 9647783-0 1998 Doxorubicin- and daunorubicin-glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS-X pump. Doxorubicin 0-11 ATP binding cassette subfamily C member 1 Homo sapiens 141-144 9647783-0 1998 Doxorubicin- and daunorubicin-glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS-X pump. Doxorubicin 0-11 ATP binding cassette subfamily C member 1 Homo sapiens 145-149 9647783-1 1998 Overexpression of the multidrug resistance-associated protein (MRP1) gene encoding a human GS-X pump in cultured cells resulted in increased cellular resistance to antitumor agents, including doxorubicin (Dox) and daunomycin (Dau), as well as certain heavy metals. Doxorubicin 192-203 ATP binding cassette subfamily C member 1 Homo sapiens 22-67 9647783-1 1998 Overexpression of the multidrug resistance-associated protein (MRP1) gene encoding a human GS-X pump in cultured cells resulted in increased cellular resistance to antitumor agents, including doxorubicin (Dox) and daunomycin (Dau), as well as certain heavy metals. Doxorubicin 192-203 ATP binding cassette subfamily C member 1 Homo sapiens 91-95 9647783-1 1998 Overexpression of the multidrug resistance-associated protein (MRP1) gene encoding a human GS-X pump in cultured cells resulted in increased cellular resistance to antitumor agents, including doxorubicin (Dox) and daunomycin (Dau), as well as certain heavy metals. Doxorubicin 205-208 ATP binding cassette subfamily C member 1 Homo sapiens 22-67 9647783-1 1998 Overexpression of the multidrug resistance-associated protein (MRP1) gene encoding a human GS-X pump in cultured cells resulted in increased cellular resistance to antitumor agents, including doxorubicin (Dox) and daunomycin (Dau), as well as certain heavy metals. Doxorubicin 205-208 ATP binding cassette subfamily C member 1 Homo sapiens 91-95 9647783-2 1998 However, studies with membrane vesicles prepared from the resistant cells revealed that Dox and Dau are poor substrates for the transport mediated by MRP/GS-X pump, suggesting that metabolic modifications of these drugs might be required for the transport. Doxorubicin 88-91 ATP binding cassette subfamily C member 1 Homo sapiens 150-153 9647783-2 1998 However, studies with membrane vesicles prepared from the resistant cells revealed that Dox and Dau are poor substrates for the transport mediated by MRP/GS-X pump, suggesting that metabolic modifications of these drugs might be required for the transport. Doxorubicin 88-91 ATP binding cassette subfamily C member 1 Homo sapiens 154-158 9679555-8 1998 Further indications for the involvement of transcriptional regulators is found in HL60 adriamycin-resistant cells which overexpress MRP, GST-pi and gamma-GCS and also have 15-20-fold more DNA-dependent protein kinase. Doxorubicin 87-97 ATP binding cassette subfamily C member 1 Homo sapiens 132-135 9485370-10 1998 Compared to previously published data for anthracyclines, the kinetic data for MRP-mediated CAL-AM pumping are most similar to those for the neutral hydroxydaunorubicin. Doxorubicin 149-168 ATP binding cassette subfamily C member 1 Homo sapiens 79-82 9443942-8 1998 Two anthracyclines, the doxorubicin derivative pirarubicin and 2"-bromo-4"-epi-DNR seemed to have a slightly higher Ka value for Pgp than for MRP. Doxorubicin 24-35 ATP binding cassette subfamily C member 1 Homo sapiens 142-145 9713512-5 1998 Using a retrovirus, we introduced the antisense RNAs of MDR1 and MRP genes into doxorubicin-selected, multidrug-resistant GAOK cells, a cell which overexpresses both MDR1 and MRP genes. Doxorubicin 80-91 ATP binding cassette subfamily C member 1 Homo sapiens 65-68 9713512-5 1998 Using a retrovirus, we introduced the antisense RNAs of MDR1 and MRP genes into doxorubicin-selected, multidrug-resistant GAOK cells, a cell which overexpresses both MDR1 and MRP genes. Doxorubicin 80-91 ATP binding cassette subfamily C member 1 Homo sapiens 175-178 9683290-4 1998 The MRP1-transfected line SKOV3-S2 was shown to be cross-resistant to doxorubicin, vincristine and etoposide but not to paclitaxel, vinblastine and platinum agents, such as cisplatin, JM216 [bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV)] and AMD473 [cis-ammine dichloro (2-methyl-pyridine) platinum (II)]. Doxorubicin 70-81 ATP binding cassette subfamily C member 1 Homo sapiens 4-8 9849488-9 1998 It was found that the positive NSAIDs were among the more potent inhibitors of [3H]-LTC4 transport into inside-out plasma membrane vesicles prepared from MRP-expressing cells, of doxorubicin efflux from preloaded cells and of glutathione-S-transferase activity. Doxorubicin 179-190 ATP binding cassette subfamily C member 1 Homo sapiens 154-157 9485370-2 1998 Although MRP has been identified as an organic anion transporter and Pgp as a transporter of certain positively charged compounds, there is considerable overlap in resistance spectrum, suggesting that both proteins transport important anticancer agents such as doxorubicin, etoposide, and vincristine. Doxorubicin 261-272 ATP binding cassette subfamily C member 1 Homo sapiens 9-12 9113101-3 1997 The present study examined the effect of BCNU on the MRP-mediated efflux of doxorubicin in the multidrug-resistant human fibrosarcoma cell line HT1080/DR4 overexpressing MRP. Doxorubicin 76-87 ATP binding cassette subfamily C member 1 Homo sapiens 170-173 9113101-7 1997 While equally effective inhibition of GR activity by BCNU was observed in parental and resistant cells, a significant increase in intracellular retention of doxorubicin was only achieved in MRP-expressing HT1080/DR4 cells. Doxorubicin 157-168 ATP binding cassette subfamily C member 1 Homo sapiens 190-193 9113101-11 1997 Depletion of intracellular GSH pools by inhibition of the GSH redox cycle or GSH de novo biosynthesis significantly inhibited MRP-mediated doxorubicin transport and restored intracellular drug concentrations in vitro. Doxorubicin 139-150 ATP binding cassette subfamily C member 1 Homo sapiens 126-129 9073310-4 1997 VX-710 at 0.5-5 microM restored senstivity of MRP-expressing HL60/ADR promyelocytic leukemia cells to the cytotoxic action of doxorubicin, etoposide and vincristine. Doxorubicin 126-137 ATP binding cassette subfamily C member 1 Homo sapiens 46-49 9495454-3 1997 MRP-expressing 250-fold doxorubicin-resistant human fibrosarcoma HT1080/DR4 tumor cells were drug sensitive to NB-506 and camptothecin (CPT) (resistance factor: 0.7 and 0.8, respectively) with no alterations of TOP-I parameters including DNA relaxation, expression of TOP-I protein and mRNA. Doxorubicin 24-35 ATP binding cassette subfamily C member 1 Homo sapiens 0-3 9815546-8 1997 There was a significant correlation between doxorubicin resistance and MRP expression levels (r = 0.422; P = 0.045). Doxorubicin 44-55 ATP binding cassette subfamily C member 1 Homo sapiens 71-74 9815546-10 1997 In summary, MRP is frequently expressed in clinical samples and cell lines from SCLC patients, and the levels correlate with doxorubicin resistance in unselected SCLC cell lines. Doxorubicin 125-136 ATP binding cassette subfamily C member 1 Homo sapiens 12-15 9816155-9 1996 The d,l-BSO-induced in vivo reversal of MRP-mediated drug resistance correlated in vitro with the restoration of intracellular doxorubicin retention in cultured HT1080/DR4 cells. Doxorubicin 127-138 ATP binding cassette subfamily C member 1 Homo sapiens 40-43 8640791-6 1996 MRP-mediated ATP-dependent transport was observed for the anticancer drug conjugates glucuronosyl [(3)H]etoposide and monocholoro-mono[(3)H]glutathionyl melphalan, but not for unmodified [(14)C]doxorubicin, [(3)H]daunorubicin, or [(3)H]vinblastine. Doxorubicin 194-205 ATP binding cassette subfamily C member 1 Homo sapiens 0-3 8937472-2 1996 Although MRP overexpression has been described in doxorubicin-selected human tumor cell lines, the murine PC-V10 and PC-V40 cell lines are members of the only reported series of vincristine-selected cell lines that overexpress mrp. Doxorubicin 50-61 ATP binding cassette subfamily C member 1 Homo sapiens 9-12 8875050-7 1996 Incubation of the cells with a modulator of MDR, PAK-104P, negated the observed drug efflux in Pgp and MRP expressing cells, which correlated with increased sensitivity of the MDR lines to doxorubicin. Doxorubicin 189-200 ATP binding cassette subfamily C member 1 Homo sapiens 103-106 8618244-0 1996 Re: How does the MRP/GS-X pump export doxorubicin? Doxorubicin 38-49 ATP binding cassette subfamily C member 1 Homo sapiens 17-20 8618244-0 1996 Re: How does the MRP/GS-X pump export doxorubicin? Doxorubicin 38-49 ATP binding cassette subfamily C member 1 Homo sapiens 21-25 9816180-3 1996 In the present study, the modulatory activity of the novel pyridine analogue PAK-104P on MRP-mediated resistance to doxorubicin and paclitaxel was investigated in two doxorubicin-selected human tumor cell lines [HT1080/DR4 (sarcoma) and HL60/ADR (leukemia)] and compared with the nonimmunosuppressive cyclosporine analogue PSC-833. Doxorubicin 116-127 ATP binding cassette subfamily C member 1 Homo sapiens 89-92 8603335-11 1996 Thus, the selection of DOX resistance in two sublines of HL-60 cells which differ in their response to retinoic acid-induced myeloid differentiation is reproducibly associated with overexpression of mdr-1 versus MRP. Doxorubicin 23-26 ATP binding cassette subfamily C member 1 Homo sapiens 212-215 8637212-0 1996 Expression of MRP and mdr1 in human gastrointestinal cancer cell lines: a correlation with resistance against doxorubicin. Doxorubicin 110-121 ATP binding cassette subfamily C member 1 Homo sapiens 14-17 9816180-4 1996 In cell lines HT1080/DR4 (MRP/lung resistance-related protein phenotype) and HL60/ADR (MRP phenotype), doxorubicin resistance was significantly higher (250-fold and 180-fold, respectively) than that to paclitaxel (6-fold and 9-fold, respectively). Doxorubicin 103-114 ATP binding cassette subfamily C member 1 Homo sapiens 26-29 9816180-4 1996 In cell lines HT1080/DR4 (MRP/lung resistance-related protein phenotype) and HL60/ADR (MRP phenotype), doxorubicin resistance was significantly higher (250-fold and 180-fold, respectively) than that to paclitaxel (6-fold and 9-fold, respectively). Doxorubicin 103-114 ATP binding cassette subfamily C member 1 Homo sapiens 87-90 7599070-1 1995 Previous studies have shown that multidrug resistance (MDR) in the doxorubicin-selected lung tumour cell lines COR-L23/R, GLC4/ADR and MOR/R is associated with overexpression of the MRP gene. Doxorubicin 67-78 ATP binding cassette subfamily C member 1 Homo sapiens 182-185 8605275-4 1996 By RT-PCR analysis of mdr1, mdr3, and mrp mRNA, these adriamycin-resistant cells showed a higher expression of the transcript of these genes than those of the parent cells. Doxorubicin 54-64 ATP binding cassette subfamily C member 1 Homo sapiens 38-41 7563208-0 1995 How does the MRP/GS-X pump export doxorubicin? Doxorubicin 34-45 ATP binding cassette subfamily C member 1 Homo sapiens 13-16 7563208-0 1995 How does the MRP/GS-X pump export doxorubicin? Doxorubicin 34-45 ATP binding cassette subfamily C member 1 Homo sapiens 17-21 7601572-0 1995 MRP gene overexpression in a human doxorubicin-resistant SCLC cell line: alterations in cellular pharmacokinetics and in pattern of cross-resistance. Doxorubicin 35-46 ATP binding cassette subfamily C member 1 Homo sapiens 0-3 8018546-8 1994 Our results corroborate the finding of MRP amplification in these doxorubicin-resistant cell lines, but, importantly, they provide information on the composition of the complex amplicon contributions from four different chromosomes. Doxorubicin 66-77 ATP binding cassette subfamily C member 1 Homo sapiens 39-42 7729950-10 1995 This study also shows that drug accumulation, topo II and MRP expression were all changed at the earliest stage of resistance development of GLC4 cells upon adriamycin selection. Doxorubicin 157-167 ATP binding cassette subfamily C member 1 Homo sapiens 58-61 7916458-3 1994 MRP-overexpressing SW-1573 cells are resistant to doxorubicin, daunorubicin, vincristine, VP-16, colchicine, and rhodamine 123, but not to 4"-(9-acridinylamino)methanesulfon-m-anisidide or taxol. Doxorubicin 50-61 ATP binding cassette subfamily C member 1 Homo sapiens 0-3 8044800-0 1994 Cloning and sequence analysis of the promoter region of the MRP gene of HL60 cells isolated for resistance to adriamycin. Doxorubicin 110-120 ATP binding cassette subfamily C member 1 Homo sapiens 60-63 33775688-5 2021 Our results demonstrated that the DOX-resistant MCF-7 and MDA-MB-231 clones exhibit higher NF-kappaB (p65) function, which is linked to the upregulated expression of ABCB1 and ABCC1 transporter proteins. Doxorubicin 34-37 ATP binding cassette subfamily C member 1 Homo sapiens 176-181 7994083-0 1994 Analysis of MRP gene expression and function in HL60 cells isolated for resistance to adriamycin. Doxorubicin 86-96 ATP binding cassette subfamily C member 1 Homo sapiens 12-15 7914748-3 1994 Thereby, we observed that actinomycin D or adriamycin administered at sublethal concentrations induced increases of mdr1 mRNA levels and resistance within 72 h. Furthermore, on leukemia cell samples collected before and after chemotherapy we checked by a complementary DNA polymerase chain reaction (cDNA-PCR) approach for similar alterations in the relative expression levels of the MDR-associated genes (a) mdr1/P-gp (b) mrp (MDR related protein), and (c) the topoisomerase II isoforms alpha and beta. Doxorubicin 43-53 ATP binding cassette subfamily C member 1 Homo sapiens 423-426 34096893-0 2021 Association of genetic polymorphisms NCF4 rs1883112, CBR3 rs1056892, and ABCC1 rs3743527 with the cardiotoxic effects of doxorubicin in children with acute lymphoblastic leukemia. Doxorubicin 121-132 ATP binding cassette subfamily C member 1 Homo sapiens 73-78 34848465-7 2021 EPI served as a substrate of P-glycoprotein and multidrug associated protein (MRP) 1 and MRP2 similarly to DOX, but the efflux efficiency of each transporter was markedly different between EPI and DOX. Doxorubicin 197-200 ATP binding cassette subfamily C member 1 Homo sapiens 48-84 34552008-9 2021 In vitro studies showed that the addition of MRP-1 inhibitors (nilotinib or avapritinib) to doxorubicin plus palifosfamide, significantly increased cell death in SK-UT-1 and CP0024 cell lines. Doxorubicin 92-103 ATP binding cassette subfamily C member 1 Homo sapiens 45-50 34869595-6 2021 The Ad-VT can reduce the resistance of MCF-7/ADR to adriamycin, which is caused by the reduction of MRP1 protein level in MCF-7/ADR cells after treatment with Ad-VT, and MRP1 can be interfered with by autophagy inhibitors. Doxorubicin 52-62 ATP binding cassette subfamily C member 1 Homo sapiens 100-104 34869595-6 2021 The Ad-VT can reduce the resistance of MCF-7/ADR to adriamycin, which is caused by the reduction of MRP1 protein level in MCF-7/ADR cells after treatment with Ad-VT, and MRP1 can be interfered with by autophagy inhibitors. Doxorubicin 52-62 ATP binding cassette subfamily C member 1 Homo sapiens 170-174 34871862-8 2022 We also observed miR-197-5p sensitizes HT1080 cells to Dox by increasing drug influx, possibly due to suppression of MDR genes (ABCC1, MVP). Doxorubicin 55-58 ATP binding cassette subfamily C member 1 Homo sapiens 128-133 34415509-9 2021 Doxorubicin-resistant MCF-7 cells had increased S1P2 and S1P3 receptor expression and show increased LPA-induced SphK1 activation, increased expression of ABCC1, ABCG2 and greater S1P secretion. Doxorubicin 0-11 ATP binding cassette subfamily C member 1 Homo sapiens 155-160 33502419-5 2021 By using human breast cancer cell line MCF-7 and MDA-MB-231, we find that doxorubicin resistance can be increased by up to 2.5 times under 30 mmHg culture condition, through ABCC1 overexpression that reduces intracellular doxorubicin concentration. Doxorubicin 74-85 ATP binding cassette subfamily C member 1 Homo sapiens 174-179 32278855-9 2020 Collectively, our data showed that miR-199a-5p regulated expression of ABCC1 and HIF-1alpha were involved in Dox resistance of NSCLC. Doxorubicin 109-112 ATP binding cassette subfamily C member 1 Homo sapiens 71-76 33493421-0 2021 Ursolic Acid Enhances Cytotoxicity of Doxorubicin-Resistant Triple-Negative Breast Cancer Cells via ZEB1-AS1/miR-186-5p/ABCC1 Axis. Doxorubicin 38-49 ATP binding cassette subfamily C member 1 Homo sapiens 120-125 32712543-11 2020 The combination of the FUC and DOX decreased ABCC1, ABCG2, and ABCB1 expression. Doxorubicin 31-34 ATP binding cassette subfamily C member 1 Homo sapiens 45-50 33493421-11 2021 Importantly, UA treatment impaired the malignant phenotypes of DOX-resistant MDA-MB-468 and MDA-MB-436 cells through ZEB1-AS1/ABCC1 axis. Doxorubicin 63-66 ATP binding cassette subfamily C member 1 Homo sapiens 126-131 33493421-12 2021 Conclusion: UA promotes TNBC cell sensitivity to DOX through inactivating ZEB1-AS1/miR-186-5p/ABCC1 signaling. Doxorubicin 49-52 ATP binding cassette subfamily C member 1 Homo sapiens 94-99 32241443-4 2020 IDAC/DOX was capable of reversing tumor multidrug resistance (MDR) through reducing multidrug resistance-associated protein 1 (MRP1) level (0.23-fold vs control group) and regulating bcl-2/bax pathway, eventually induced more apoptosis in MCF-7/ADR cells. Doxorubicin 5-8 ATP binding cassette subfamily C member 1 Homo sapiens 84-125 32606732-0 2020 CircFoxo3 Promotes Adriamycin Resistance Through Regulation of miR-199a-5p/ATP Binding Cassette Subfamily C Member 1 Axis in Hepatocellular Carcinoma. Doxorubicin 19-29 ATP binding cassette subfamily C member 1 Homo sapiens 75-116 32241443-4 2020 IDAC/DOX was capable of reversing tumor multidrug resistance (MDR) through reducing multidrug resistance-associated protein 1 (MRP1) level (0.23-fold vs control group) and regulating bcl-2/bax pathway, eventually induced more apoptosis in MCF-7/ADR cells. Doxorubicin 5-8 ATP binding cassette subfamily C member 1 Homo sapiens 127-131 31704984-3 2019 Downregulating EGFR and MRP1 inhibits T-DM1R-JIMT1 cell growth and re-sensitizes T-DM1R cells to doxorubicin, suggesting that dual targeting EGFR and MRP1 could serve as a therapeutic approach to overcome T-DM1 resistance. Doxorubicin 97-108 ATP binding cassette subfamily C member 1 Homo sapiens 24-28 32340377-2 2020 The results showed that DOX-induced cell death was enhanced by ATG/DOX co-treatment in a concentration-dependent manner and that this was associated with increased DOX uptake and the suppression of multidrug resistance-associated protein 1 (MRP1) gene expression in MDA-MB-231 cells. Doxorubicin 67-70 ATP binding cassette subfamily C member 1 Homo sapiens 241-245 32010961-5 2020 This association is highly drug-specific for subgroups treated with the MRP1 substrates cyclophosphamide (log-rank p = 0.0011) and doxorubicin (log-rank p = 0.0088) independent of age and tumor stage, whereas no association was found in individuals treated with tamoxifen (log-rank p = 0.13). Doxorubicin 131-142 ATP binding cassette subfamily C member 1 Homo sapiens 72-76 32340377-2 2020 The results showed that DOX-induced cell death was enhanced by ATG/DOX co-treatment in a concentration-dependent manner and that this was associated with increased DOX uptake and the suppression of multidrug resistance-associated protein 1 (MRP1) gene expression in MDA-MB-231 cells. Doxorubicin 24-27 ATP binding cassette subfamily C member 1 Homo sapiens 198-239 32340377-2 2020 The results showed that DOX-induced cell death was enhanced by ATG/DOX co-treatment in a concentration-dependent manner and that this was associated with increased DOX uptake and the suppression of multidrug resistance-associated protein 1 (MRP1) gene expression in MDA-MB-231 cells. Doxorubicin 24-27 ATP binding cassette subfamily C member 1 Homo sapiens 241-245 32340377-2 2020 The results showed that DOX-induced cell death was enhanced by ATG/DOX co-treatment in a concentration-dependent manner and that this was associated with increased DOX uptake and the suppression of multidrug resistance-associated protein 1 (MRP1) gene expression in MDA-MB-231 cells. Doxorubicin 67-70 ATP binding cassette subfamily C member 1 Homo sapiens 241-245 31646427-6 2019 The impact of PLGA-Crt NPs on the functioning of MRP transporters was assessed by the doxorubicin efflux assay. Doxorubicin 86-97 ATP binding cassette subfamily C member 1 Homo sapiens 49-52 31043590-6 2019 Mechanistically, Matrigel/beta1 integrin interaction enhanced T-ALL chemoresistance by promoting doxorubicin efflux through the activation of the ABCC1 drug transporter. Doxorubicin 97-108 ATP binding cassette subfamily C member 1 Homo sapiens 146-151 31401398-0 2019 Doxorubicin as a fluorescent reporter identifies novel MRP1 (ABCC1) inhibitors missed by calcein-based high content screening of anticancer agents. Doxorubicin 0-11 ATP binding cassette subfamily C member 1 Homo sapiens 55-59 31401398-0 2019 Doxorubicin as a fluorescent reporter identifies novel MRP1 (ABCC1) inhibitors missed by calcein-based high content screening of anticancer agents. Doxorubicin 0-11 ATP binding cassette subfamily C member 1 Homo sapiens 61-66 31401398-8 2019 Six drugs (afatinib, celecoxib, doramapimod, mifepristone, MK-2206 and rosiglitazone) were evaluated for their ability to reverse resistance of MRP1-overexpressing H69AR lung cancer cells against vincristine, doxorubicin and etoposide. Doxorubicin 209-220 ATP binding cassette subfamily C member 1 Homo sapiens 144-148 30945389-6 2019 Our in vitro studies showed that Tan IIA could enhance the sensitivity of breast cancer cells to Dox through inhibiting the PTEN/AKT pathway and downregulating the expression of efflux ABC transporters including P-gp, BCRP, and MRP1. Doxorubicin 97-100 ATP binding cassette subfamily C member 1 Homo sapiens 228-232 30232176-4 2018 Calcitriol and calcipotriol consistently displayed a potent inhibitory activity on MRP1-mediated doxorubicin and calcein efflux in MRP1-overexpressing H69AR and HEK293/MRP1 cells. Doxorubicin 97-108 ATP binding cassette subfamily C member 1 Homo sapiens 83-87 31009836-0 2019 Vielanin P enhances the cytotoxicity of doxorubicin via the inhibition of PI3K/Nrf2-stimulated MRP1 expression in MCF-7 and K562 DOX-resistant cell lines. Doxorubicin 40-51 ATP binding cassette subfamily C member 1 Homo sapiens 95-99 31009836-0 2019 Vielanin P enhances the cytotoxicity of doxorubicin via the inhibition of PI3K/Nrf2-stimulated MRP1 expression in MCF-7 and K562 DOX-resistant cell lines. Doxorubicin 129-132 ATP binding cassette subfamily C member 1 Homo sapiens 95-99 31009836-13 2019 In addition, VP reversed MRP1 protein levels and the accumulation of DOX and CFDA in MRP1-overexpressing MCF-7 and K562 cells. Doxorubicin 69-72 ATP binding cassette subfamily C member 1 Homo sapiens 85-89 30609135-7 2019 The results of the present study demonstrated that treatment of SKOV3 with 55 muM of RES and 250 nM of DOX simultaneously increased cell viability in CSCs to DOX after 24 and 48 hours by increasing the expression of Bcl-2-associated X protein (BAX) and caspase-3 genes, and decreased the expression and function of multidrug resistance protein 1 (MDR1) and multidrug resistance-associated protein 1 (MRP1) genes indicated by intracellular the rhodamine 123 content. Doxorubicin 103-106 ATP binding cassette subfamily C member 1 Homo sapiens 357-398 30609135-7 2019 The results of the present study demonstrated that treatment of SKOV3 with 55 muM of RES and 250 nM of DOX simultaneously increased cell viability in CSCs to DOX after 24 and 48 hours by increasing the expression of Bcl-2-associated X protein (BAX) and caspase-3 genes, and decreased the expression and function of multidrug resistance protein 1 (MDR1) and multidrug resistance-associated protein 1 (MRP1) genes indicated by intracellular the rhodamine 123 content. Doxorubicin 103-106 ATP binding cassette subfamily C member 1 Homo sapiens 400-404 30037815-11 2018 ABCB1 and ABCC1 RNA expression levels decreased by 58.47-fold and 1.47-fold, respectively, on day 5 of the cycle.Conclusions: Combination of MRP-1/P-gp inhibitor, nilotinib, as coadjuvant with doxorubicin is feasible; it appears not to add substantial toxicity compared with doxorubicin alone. Doxorubicin 193-204 ATP binding cassette subfamily C member 1 Homo sapiens 10-15 30486290-0 2018 Nobiletin Enhances Chemosensitivity to Adriamycin through Modulation of the Akt/GSK3beta/beta-Catenin/MYCN/MRP1 Signaling Pathway in A549 Human Non-Small-Cell Lung Cancer Cells. Doxorubicin 39-49 ATP binding cassette subfamily C member 1 Homo sapiens 107-111 30466628-12 2018 Furthermore, using doxorubicin-sensitive cell line SNU-719 and doxorubicin-resistant cell lines SNU-719R and SNU-620, we revealed the pivotal roles of MRP1. Doxorubicin 19-30 ATP binding cassette subfamily C member 1 Homo sapiens 151-155 30466628-12 2018 Furthermore, using doxorubicin-sensitive cell line SNU-719 and doxorubicin-resistant cell lines SNU-719R and SNU-620, we revealed the pivotal roles of MRP1. Doxorubicin 63-74 ATP binding cassette subfamily C member 1 Homo sapiens 151-155 30466628-14 2018 Importantly, inhibition of MRP1 function enhanced cell cycle arrest, increased apoptosis and induced autophagic cell death which contributed to the capability of tanshinone IIA to potentiate the anticancer effect of doxorubicin in drug-resistant gastric cancer cells. Doxorubicin 216-227 ATP binding cassette subfamily C member 1 Homo sapiens 27-31 30037815-11 2018 ABCB1 and ABCC1 RNA expression levels decreased by 58.47-fold and 1.47-fold, respectively, on day 5 of the cycle.Conclusions: Combination of MRP-1/P-gp inhibitor, nilotinib, as coadjuvant with doxorubicin is feasible; it appears not to add substantial toxicity compared with doxorubicin alone. Doxorubicin 193-204 ATP binding cassette subfamily C member 1 Homo sapiens 141-146 30037815-11 2018 ABCB1 and ABCC1 RNA expression levels decreased by 58.47-fold and 1.47-fold, respectively, on day 5 of the cycle.Conclusions: Combination of MRP-1/P-gp inhibitor, nilotinib, as coadjuvant with doxorubicin is feasible; it appears not to add substantial toxicity compared with doxorubicin alone. Doxorubicin 275-286 ATP binding cassette subfamily C member 1 Homo sapiens 10-15 30037815-11 2018 ABCB1 and ABCC1 RNA expression levels decreased by 58.47-fold and 1.47-fold, respectively, on day 5 of the cycle.Conclusions: Combination of MRP-1/P-gp inhibitor, nilotinib, as coadjuvant with doxorubicin is feasible; it appears not to add substantial toxicity compared with doxorubicin alone. Doxorubicin 275-286 ATP binding cassette subfamily C member 1 Homo sapiens 141-146 30188727-7 2018 The DNA sequence within the nanoparticle specifically binds to an mRNA encoding an important drug resistance factor, MRP1, inside cancer cells, releasing a potent anticancer drug doxorubicin. Doxorubicin 179-190 ATP binding cassette subfamily C member 1 Homo sapiens 117-121 30188727-8 2018 This event triggers a turn-on fluorescence emission along with a downregulation of the MRP1 drug efflux pump, a main resistance factor for doxorubicin, yielding a remarkable improvement in therapeutic efficacy against drug-resistant cancer cells. Doxorubicin 139-150 ATP binding cassette subfamily C member 1 Homo sapiens 87-91 29541235-9 2018 As a potential explanation for this doxorubicin resistance, significantly increased mRNA expression levels of ATP-binding cassette ABCB1 (multidrug resistance protein 1) and ABCC1 (multidrug resistance-associated protein 1) were observed by reverse transcription-quantitative polymerase chain reaction. Doxorubicin 36-47 ATP binding cassette subfamily C member 1 Homo sapiens 174-179 29615646-0 2018 Bile Acids Increase Doxorubicin Sensitivity in ABCC1-expressing Tumour Cells. Doxorubicin 20-31 ATP binding cassette subfamily C member 1 Homo sapiens 47-52 29615646-5 2018 In this study, we demonstrate the ability of two bile acids [beta-cholanic acid (urso-cholanic acid) and deoxycholic acid] to specifically inhibit ABCC1-mediated drug transport, augmenting doxorubicin accumulation in breast and lung tumour cells selected for doxorubicin resistance through overexpression of the ABCC1 (but not ABCB1) drug transporter. Doxorubicin 189-200 ATP binding cassette subfamily C member 1 Homo sapiens 147-152 29615646-5 2018 In this study, we demonstrate the ability of two bile acids [beta-cholanic acid (urso-cholanic acid) and deoxycholic acid] to specifically inhibit ABCC1-mediated drug transport, augmenting doxorubicin accumulation in breast and lung tumour cells selected for doxorubicin resistance through overexpression of the ABCC1 (but not ABCB1) drug transporter. Doxorubicin 259-270 ATP binding cassette subfamily C member 1 Homo sapiens 147-152 29615646-6 2018 The bile acids could also restore uptake and sensitivity to doxorubicin in human endothelial kidney cells genetically engineered to overexpress the ABCC1 drug transporter. Doxorubicin 60-71 ATP binding cassette subfamily C member 1 Homo sapiens 148-153 29475141-5 2018 The results showed that Que could increase intracellular accumulation of Dox in breast cancer cells through down-regulating the expression of efflux ABC transporters including P-gp, BCRP and MRP1, which can effectively eliminate cancerous cells including breast cancer stem cells (BCSCs), thereby potentiating the anti-tumor effect of Dox. Doxorubicin 73-76 ATP binding cassette subfamily C member 1 Homo sapiens 191-195 29475141-5 2018 The results showed that Que could increase intracellular accumulation of Dox in breast cancer cells through down-regulating the expression of efflux ABC transporters including P-gp, BCRP and MRP1, which can effectively eliminate cancerous cells including breast cancer stem cells (BCSCs), thereby potentiating the anti-tumor effect of Dox. Doxorubicin 335-338 ATP binding cassette subfamily C member 1 Homo sapiens 191-195 29541235-9 2018 As a potential explanation for this doxorubicin resistance, significantly increased mRNA expression levels of ATP-binding cassette ABCB1 (multidrug resistance protein 1) and ABCC1 (multidrug resistance-associated protein 1) were observed by reverse transcription-quantitative polymerase chain reaction. Doxorubicin 36-47 ATP binding cassette subfamily C member 1 Homo sapiens 181-222 29445446-9 2018 Meanwhile, ABCC1 and MDR-1 were significantly increased in Caki-2/VBL and Caki-2/DOX cells. Doxorubicin 81-84 ATP binding cassette subfamily C member 1 Homo sapiens 11-16 29747752-6 2018 RESULTS: Our data found that the intracellular accumulation of rhodamine-123 (Rh123) and doxorubicin (ADR) were increased, the sensitivity of BEL/5-FU cells to chemotherapeutic drugs were increased, and the expressions of ABCB1, ABCC1 and ABCC2 were all down-regulated, which indicated that the functions and expressions of ABCB1, ABCC1 and ABCC2 efflux pump were inhibited by quercetin treatment. Doxorubicin 89-100 ATP binding cassette subfamily C member 1 Homo sapiens 229-234 29747752-6 2018 RESULTS: Our data found that the intracellular accumulation of rhodamine-123 (Rh123) and doxorubicin (ADR) were increased, the sensitivity of BEL/5-FU cells to chemotherapeutic drugs were increased, and the expressions of ABCB1, ABCC1 and ABCC2 were all down-regulated, which indicated that the functions and expressions of ABCB1, ABCC1 and ABCC2 efflux pump were inhibited by quercetin treatment. Doxorubicin 89-100 ATP binding cassette subfamily C member 1 Homo sapiens 331-336 28214549-6 2017 CONCLUSIONS: Both BCRP and MRP1 were localized in mitochondria and participated to the reduction of mitochondrial accumulation of DOX in MCF-7doxR. Doxorubicin 130-133 ATP binding cassette subfamily C member 1 Homo sapiens 27-31 29463376-5 2018 Results demonstrated that the function and expression of MRP1 could be successfully inhibited by CsA as a reversal agent from the pharmaceutical preparation, leading to dramatic increase of intracellular concentration of Dox. Doxorubicin 221-224 ATP binding cassette subfamily C member 1 Homo sapiens 57-61 28881292-8 2017 Suppression of UBE2C expression by RNA interference led to decrease the mRNA expressions of BCRP, MRP1 and P-gp in doxorubicin-treated MDA-MB-231 cells. Doxorubicin 115-126 ATP binding cassette subfamily C member 1 Homo sapiens 98-102 28762597-9 2017 Knockdown of visfatin can down-regulate the expression of ABCC1 in Dox-resistant NSCLC cells. Doxorubicin 67-70 ATP binding cassette subfamily C member 1 Homo sapiens 58-63 29069754-0 2017 LncRNA FENDRR sensitizes doxorubicin-resistance of osteosarcoma cells through down-regulating ABCB1 and ABCC1. Doxorubicin 25-36 ATP binding cassette subfamily C member 1 Homo sapiens 104-109 29069754-6 2017 Together, our study demonstrated that lncRNA FENDRR may act as an inhibitory molecule of doxorubicin-resistance through down-regulating the expression of ABCB1 and ABCC1 genes in osteosarcoma cells. Doxorubicin 89-100 ATP binding cassette subfamily C member 1 Homo sapiens 164-169 29085470-3 2017 The SHG44/DOX cells grew continually in 0.1 microg/ml DOX and expressed increased levels of mRNA of multidrug resistance genes [multidrug resistance 1 (MDR1), multidrug resistance-associated protein 1 (MRP1) and lung resistance protein (LRP)] compared with the parental SHG44 cells. Doxorubicin 10-13 ATP binding cassette subfamily C member 1 Homo sapiens 159-200 29085470-3 2017 The SHG44/DOX cells grew continually in 0.1 microg/ml DOX and expressed increased levels of mRNA of multidrug resistance genes [multidrug resistance 1 (MDR1), multidrug resistance-associated protein 1 (MRP1) and lung resistance protein (LRP)] compared with the parental SHG44 cells. Doxorubicin 10-13 ATP binding cassette subfamily C member 1 Homo sapiens 202-206 29085470-5 2017 In addition, the levels of MDR1, MRP1 and LRP were downregulated by this traditional Chinese medicine, coupled with increased intracellular DOX concentrations. Doxorubicin 140-143 ATP binding cassette subfamily C member 1 Homo sapiens 33-37 28711493-6 2017 Here we further report ZD55-shMYCN re-sensitized doxorubicin-resistant cells to doxorubicin (as shown by reduced proliferation, increased apoptosis, and inhibited cell migration), and reduced the in vivo growth rate of neuroblastoma xenografts by down-regulation of MRP expression. Doxorubicin 49-60 ATP binding cassette subfamily C member 1 Homo sapiens 266-269 29104509-3 2017 In a previous study, we have reported that a novel antisense lncRNA FOXF1-AS1, also known as FENDRR, could sensitize doxorubicin-resistance of OS cells through down-regulating ABCB1 and ABCC1. Doxorubicin 117-128 ATP binding cassette subfamily C member 1 Homo sapiens 186-191 27878697-12 2017 It was speculated that the NFkappaB pathway directly acts on doxorubicin-induced MDR1 and MRP1 expression in MCF-7/Dox cells. Doxorubicin 61-72 ATP binding cassette subfamily C member 1 Homo sapiens 90-94 27878697-12 2017 It was speculated that the NFkappaB pathway directly acts on doxorubicin-induced MDR1 and MRP1 expression in MCF-7/Dox cells. Doxorubicin 115-118 ATP binding cassette subfamily C member 1 Homo sapiens 90-94 27250110-6 2017 The cellular uptake of DOX increased upon addition of free CQ, indicating that CQ may interact with P-gp and MRP1; however, the expressions of P-gp and MRP1 remained unchanged. Doxorubicin 23-26 ATP binding cassette subfamily C member 1 Homo sapiens 109-113 28214549-4 2017 In these DOX-resistant cells, breast cancer resistance protein (BCRP) and multidrug resistance-associated protein (MRP1) were expressed and localized in mitochondria (confocal microscopy and confocal spectral imaging studies). Doxorubicin 9-12 ATP binding cassette subfamily C member 1 Homo sapiens 115-119 28214549-5 2017 In addition, mitochondrial accumulation of DOX was increased by BCRP and MRP1 inhibitors and, to a lower extent, by the mitochondrial ATP synthase inhibitor, oligomycin, in MCF-7doxR. Doxorubicin 43-46 ATP binding cassette subfamily C member 1 Homo sapiens 73-77 27822706-10 2017 CONCLUSIONS: From our data we conclude that targeting of CXCR4 and FAK may overcome ABCB1 and ABCC1-dependent DOX resistance in NSCLC cells and that simultaneous treatment of these cells with DOX may potentiate the anti-invasive effects of CXCR4 and FAK inhibitors. Doxorubicin 110-113 ATP binding cassette subfamily C member 1 Homo sapiens 94-99 28258008-9 2017 Inhibition of MRP1 activity was further validated using flow cytometry and confocal microscopy for the respective detection of calcein and doxorubicin in MRP1-overexpressing cells. Doxorubicin 139-150 ATP binding cassette subfamily C member 1 Homo sapiens 14-18 28258008-9 2017 Inhibition of MRP1 activity was further validated using flow cytometry and confocal microscopy for the respective detection of calcein and doxorubicin in MRP1-overexpressing cells. Doxorubicin 139-150 ATP binding cassette subfamily C member 1 Homo sapiens 154-158 27822706-10 2017 CONCLUSIONS: From our data we conclude that targeting of CXCR4 and FAK may overcome ABCB1 and ABCC1-dependent DOX resistance in NSCLC cells and that simultaneous treatment of these cells with DOX may potentiate the anti-invasive effects of CXCR4 and FAK inhibitors. Doxorubicin 192-195 ATP binding cassette subfamily C member 1 Homo sapiens 94-99 26722004-2 2016 MRP-1 is also expressed in mitochondria, and we have examined the submitochondrial localization of MRP-1 and investigated the mechanism of MRP-1 transport and role of this organelle in the response to doxorubicin. Doxorubicin 201-212 ATP binding cassette subfamily C member 1 Homo sapiens 0-5 27731405-5 2016 Furthermore, DOX/RES-loaded NPS could overcome DOX resistance by inhibiting the expression of drug resistance-related protein such as P-gp, MRP-1 and BCRP, and induce apoptosis through down-regulating the expression of NF-kappaB and BCL-2. Doxorubicin 13-16 ATP binding cassette subfamily C member 1 Homo sapiens 140-145 27731405-5 2016 Furthermore, DOX/RES-loaded NPS could overcome DOX resistance by inhibiting the expression of drug resistance-related protein such as P-gp, MRP-1 and BCRP, and induce apoptosis through down-regulating the expression of NF-kappaB and BCL-2. Doxorubicin 47-50 ATP binding cassette subfamily C member 1 Homo sapiens 140-145 27487127-0 2016 miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1. Doxorubicin 36-47 ATP binding cassette subfamily C member 1 Homo sapiens 61-102 27487127-3 2016 And MRP1 level increased in doxorubicin resistant MCF-7 cells compared with parental MCF-7 cells. Doxorubicin 28-39 ATP binding cassette subfamily C member 1 Homo sapiens 4-8 27487127-6 2016 In the process of constructing MCF-7 doxorubicin resistant cell line, escalating doxorubicin markedly decreased miR-145 level, following by increased MRP1 level. Doxorubicin 37-48 ATP binding cassette subfamily C member 1 Homo sapiens 150-154 27487127-6 2016 In the process of constructing MCF-7 doxorubicin resistant cell line, escalating doxorubicin markedly decreased miR-145 level, following by increased MRP1 level. Doxorubicin 81-92 ATP binding cassette subfamily C member 1 Homo sapiens 150-154 27487127-9 2016 Taken together, our study revealed miR-145 sensitizes breast cancer to doxorubicin by targeting MRP1 and indicated the potential application in developing MRP1 inhibitor. Doxorubicin 71-82 ATP binding cassette subfamily C member 1 Homo sapiens 96-100 27487127-9 2016 Taken together, our study revealed miR-145 sensitizes breast cancer to doxorubicin by targeting MRP1 and indicated the potential application in developing MRP1 inhibitor. Doxorubicin 71-82 ATP binding cassette subfamily C member 1 Homo sapiens 155-159 27476287-4 2016 P-gp-dependent, MRP-, LRP-dependent multidrug resistance) and MES-SA/DX5 (P-gp-dependent resistance to doxorubicin) are also resistant to the 5H-indolo[2,3-b]indoloquinoline O-aminoglycosides tested. Doxorubicin 103-114 ATP binding cassette subfamily C member 1 Homo sapiens 16-19 26722004-5 2016 The effect of disrupting mitochondrial MRP-1-dependent efflux activity on the cytotoxic effect of doxorubicin was investigated by counting viable cell number. Doxorubicin 98-109 ATP binding cassette subfamily C member 1 Homo sapiens 39-44 26722004-8 2016 Disruption of mitochondrial MRP-1-dependent efflux significantly increases the cytotoxic effect of doxorubicin (combination index, <0.9). Doxorubicin 99-110 ATP binding cassette subfamily C member 1 Homo sapiens 28-33 26722004-9 2016 For the first time, we have demonstrated that mitochondrial MRP-1 is expressed in the outer mitochondrial membrane and is a client protein of HSP90beta, where it may play a role in the doxorubicin-induced resistance of ES.-Roundhill, E., Turnbull, D., Burchill, S. Localization of MRP-1 to the outer mitochondrial membrane by the chaperone protein HSP90beta. Doxorubicin 185-196 ATP binding cassette subfamily C member 1 Homo sapiens 60-65 26722004-9 2016 For the first time, we have demonstrated that mitochondrial MRP-1 is expressed in the outer mitochondrial membrane and is a client protein of HSP90beta, where it may play a role in the doxorubicin-induced resistance of ES.-Roundhill, E., Turnbull, D., Burchill, S. Localization of MRP-1 to the outer mitochondrial membrane by the chaperone protein HSP90beta. Doxorubicin 185-196 ATP binding cassette subfamily C member 1 Homo sapiens 281-286 26318721-0 2015 MicroRNA-134 modulates resistance to doxorubicin in human breast cancer cells by downregulating ABCC1. Doxorubicin 37-48 ATP binding cassette subfamily C member 1 Homo sapiens 96-101 28276667-0 2016 Sulindac sulfide selectively increases sensitivity of ABCC1 expressing tumor cells to doxorubicin and glutathione depletion. Doxorubicin 86-97 ATP binding cassette subfamily C member 1 Homo sapiens 54-59 26548759-5 2016 We found that in our OS cell lines this agent was able to revert the ABCB1/ABCC1-mediated resistance against doxorubicin, as well as against the drugs used in second-line OS treatments that are substrates of these transporters (taxotere, etoposide, vinorelbine). Doxorubicin 109-120 ATP binding cassette subfamily C member 1 Homo sapiens 75-80 26318721-6 2015 The expression of ABCC1 was significantly upregulated in doxorubicin-resistant or -sensitive breast cancer tissues and MCF-7/ADR cell lines. Doxorubicin 57-68 ATP binding cassette subfamily C member 1 Homo sapiens 18-23 26318721-8 2015 CONCLUSION: MicroRNA-134 modulates resistance to doxorubicin in breast cancer cells by downregulating the expression of ABCC1 which is known to encode the multidrug resistance-associated protein 1. Doxorubicin 49-60 ATP binding cassette subfamily C member 1 Homo sapiens 120-125 26318721-8 2015 CONCLUSION: MicroRNA-134 modulates resistance to doxorubicin in breast cancer cells by downregulating the expression of ABCC1 which is known to encode the multidrug resistance-associated protein 1. Doxorubicin 49-60 ATP binding cassette subfamily C member 1 Homo sapiens 155-196 26362310-6 2015 In breast cell lines, doxorubicin induced MRP1 expression and function (non-linear regression p < 0.004). Doxorubicin 22-33 ATP binding cassette subfamily C member 1 Homo sapiens 42-46 26600514-0 2015 Meloxicam increases intracellular accumulation of doxorubicin via downregulation of multidrug resistance-associated protein 1 (MRP1) in A549 cells. Doxorubicin 50-61 ATP binding cassette subfamily C member 1 Homo sapiens 84-125 26600514-0 2015 Meloxicam increases intracellular accumulation of doxorubicin via downregulation of multidrug resistance-associated protein 1 (MRP1) in A549 cells. Doxorubicin 50-61 ATP binding cassette subfamily C member 1 Homo sapiens 127-131 26600514-4 2015 In order to unravel the molecular mechanisms involved in doxorubicin accumulation, we measured the levels of multidrug resistance-associated protein (MRP)-transporter protein activity and expression by western blotting, since this has been implicated in meloxicam action as well as in chemoresistance. Doxorubicin 57-68 ATP binding cassette subfamily C member 1 Homo sapiens 150-153 26600514-5 2015 We found that, in A549 cells, meloxicam could increase intracellular accumulation of doxorubicin, a substrate for MRP, through inhibition of cellular export. Doxorubicin 85-96 ATP binding cassette subfamily C member 1 Homo sapiens 114-117 26362310-7 2015 In the breast cancer line T47D, doxorubicin activated Notch1 and, critically, inhibition of Notch1 activation with the gamma-secretase inhibitor DAPT abolished the doxorubicin-induced increase in MRP1 expression and function (t-test p < 0.05), resulting in enhanced cellular retention of doxorubicin and increased doxorubicin-induced apoptosis (t-test p = 0.0002). Doxorubicin 32-43 ATP binding cassette subfamily C member 1 Homo sapiens 196-200 26362310-7 2015 In the breast cancer line T47D, doxorubicin activated Notch1 and, critically, inhibition of Notch1 activation with the gamma-secretase inhibitor DAPT abolished the doxorubicin-induced increase in MRP1 expression and function (t-test p < 0.05), resulting in enhanced cellular retention of doxorubicin and increased doxorubicin-induced apoptosis (t-test p = 0.0002). Doxorubicin 164-175 ATP binding cassette subfamily C member 1 Homo sapiens 196-200 26362310-7 2015 In the breast cancer line T47D, doxorubicin activated Notch1 and, critically, inhibition of Notch1 activation with the gamma-secretase inhibitor DAPT abolished the doxorubicin-induced increase in MRP1 expression and function (t-test p < 0.05), resulting in enhanced cellular retention of doxorubicin and increased doxorubicin-induced apoptosis (t-test p = 0.0002). Doxorubicin 164-175 ATP binding cassette subfamily C member 1 Homo sapiens 196-200 26362310-7 2015 In the breast cancer line T47D, doxorubicin activated Notch1 and, critically, inhibition of Notch1 activation with the gamma-secretase inhibitor DAPT abolished the doxorubicin-induced increase in MRP1 expression and function (t-test p < 0.05), resulting in enhanced cellular retention of doxorubicin and increased doxorubicin-induced apoptosis (t-test p = 0.0002). Doxorubicin 164-175 ATP binding cassette subfamily C member 1 Homo sapiens 196-200 26063481-0 2015 Lapatinib sensitizes quiescent MDA-MB-231 breast cancer cells to doxorubicin by inhibiting the expression of multidrug resistance-associated protein-1. Doxorubicin 65-76 ATP binding cassette subfamily C member 1 Homo sapiens 109-150 26063481-8 2015 The inhibition of EGFR signaling by the treatment with lapatinib suppressed the expression of multidrug resistance-associated protein-1 (MRP-1), leading to increased cytotoxicity of doxorubicin to tumorspheres. Doxorubicin 182-193 ATP binding cassette subfamily C member 1 Homo sapiens 94-135 26063481-8 2015 The inhibition of EGFR signaling by the treatment with lapatinib suppressed the expression of multidrug resistance-associated protein-1 (MRP-1), leading to increased cytotoxicity of doxorubicin to tumorspheres. Doxorubicin 182-193 ATP binding cassette subfamily C member 1 Homo sapiens 137-142 26063481-9 2015 Furthermore, blockade of the PI3K/AKT and p38 MAPK signaling pathways resulted in a remarkable decrease in the expression of MRP-1 in doxorubicin-treated tumorspheres. Doxorubicin 134-145 ATP binding cassette subfamily C member 1 Homo sapiens 125-130 26063481-10 2015 These results demonstrate that lapatinib sensitizes quiescent MDA-MB-231 breast cancer cells to doxorubicin by inhibiting doxorubicin-induced MRP-1 expression via PI3K/AKT and p38 MAPK signaling pathways. Doxorubicin 96-107 ATP binding cassette subfamily C member 1 Homo sapiens 142-147 26063481-10 2015 These results demonstrate that lapatinib sensitizes quiescent MDA-MB-231 breast cancer cells to doxorubicin by inhibiting doxorubicin-induced MRP-1 expression via PI3K/AKT and p38 MAPK signaling pathways. Doxorubicin 122-133 ATP binding cassette subfamily C member 1 Homo sapiens 142-147 25934574-7 2015 In addition, tRNA-carried pre-miR-1291 suppressed the growth of MCF-7 and PANC-1 cells in a dose-dependent manner, and significantly enhanced the sensitivity of ABCC1-overexpressing PANC-1 cells to doxorubicin. Doxorubicin 198-209 ATP binding cassette subfamily C member 1 Homo sapiens 161-166